WVSHP Logo Contact Information
News & Events

News from WVSHP

WVSHP Annual Residency Showcase Updated 10/10/2018: Driving directions, parking Information, and Showcase Residency Programs list now available. SAVE THE DATE WVSHP Annual Residency Showcase Saturday October 20th, 2018 Being Held at the WVU School of Pharmacy Registration coming soon. (Click for more...) 2019 Spring Meeting - Save the date SAVE THE DATE for the Spring Meeting 2019 April 26th and 27th, 2019 Embassy Suites, Charleston, WV (Click for more...) ASHP and ACPE revised guidelines ASHP and the Accreditation Council for Pharmacy Education (ACPE) just released revisions to the Accreditation Standards for Pharmacy Technician Educat (Click for more...)

News from elsewhere...
Games and Events: A New Era of Coopetition in Pharma R&D 12/8/2018 1:11:27 PM Although R&D competition remains as fierce as ever, many pharmaceutical companies engage in various types of cooperation and partnership ventures to help drive innovation. The goal of coopetition — when companies cooperate on certain projects while maintaining a competitive stance — is to make drug development more efficient and effective. Events that foster the competitive […] (Click for more...) Calcium Chloride Injection 12/7/2018 7:00:00 PM Drug: Calcium Chloride Injection, Revision Date: Sat, 08 Dec 2018 (Click for more...) Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution 12/7/2018 7:00:00 PM Drug: Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution, Revision Date: Sat, 08 Dec 2018 (Click for more...) Enalaprilat Injection 12/7/2018 7:00:00 PM Drug: Enalaprilat Injection, Revision Date: Sat, 08 Dec 2018 (Click for more...) Epinephrine Injection 12/7/2018 7:00:00 PM Drug: Epinephrine Injection, Revision Date: Sat, 08 Dec 2018 (Click for more...) Octreotide Injection 12/7/2018 7:00:00 PM Drug: Octreotide Injection, Revision Date: Sat, 08 Dec 2018 (Click for more...) Drug maker pays $360 million to settle investigation into charity kickbacks 12/7/2018 12:42:19 PM Drug maker pays $360 million to settle investigation into charity kickbacks Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 Federal prosecutors announced Thursday that Actelion Pharmaceuticals has agreed to a $360 million settlement stemming from an investigation into whether the company illegally funneled kickbacks through a patient-assistance charity. Actelion, which was acquired by Johnson & Johnson in 2017, manufactures expensive drugs to treat a rare lung condition. It is the latest pharmaceutical company to settle federal inquiries into its ties to patient-assistance groups. "Pharmaceutical companies cannot have it both ways—they cannot continue to increase drug prices while engaging in conduct designed to defeat the mechanisms that Congress designed to check such prices and then expect Medicare to pay for the ballooning costs," said Joseph Hunt, an assistant attorney general for the Justice Department. In 2014 and 2015, prosecutors said, Actelion raised the price of its main drug, bosentan (Tracleer), by nearly 30 times the rate of inflation. Actelion admitted no wrongdoing in its settlement. Johnson & Johnson was not implicated in the allegations since the activity under scrutiny took place before Actelion was acquired. (Click for more...) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer 12/7/2018 12:42:15 PM First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 The IMpower133 clinical trial investigated whether adding a checkpoint inhibitor of programmed death signaling might improve the benefits of chemotherapy in patients with late-stage small-cell lung cancer. The Phase III study involved about 400 treatment-naive patients who were randomly allocated to one of two treatment groups. All underwent chemotherapy with carboplatin and etoposide, but one-half also received atezolizumab. The other patients received placebo. Treatment was administered during an induction phase consisting of four 21-day cycles and an ensuing maintenance phase that ended when the patient experienced unacceptable toxic effects or disease progression, or when the therapy ceased to provide clinical benefit. Followup took place after a median 13.9 months, at which time overall survival was measured at a median 12.3 months in the atezolizumab group compared with 10.3 months in the control group. Median progression-free survival, meanwhile, was 5.2 months vs. 4.3 months, respectively. The evidence supports the addition of atezolizumab to chemotherapy as a first-line therapy for extensive-stage small-cell lung cancer, the researchers concluded. (Click for more...) AmerisourceBergen Foundation donates nearly 1m drug deactivation resources 12/7/2018 12:42:15 PM AmerisourceBergen Foundation donates nearly 1m drug deactivation resources Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 The AmerisourceBergen Foundation reports that it has distributed approximately 1 million drug deactivation resources through its Safe Disposal Support Program in 44 states and to 140 organizations nationwide. In addition, the foundation has worked with more than 20 not-for-profit groups to provide funding against the opioid crisis. "The epidemic of opioid misuse is a complex, multifaceted problem—and one that demands action, attention and a collaborative approach," said Gina Clark, president of the AmerisourceBergen Foundation. "I look forward to the next phase of our foundation's work as we continue to identify partnerships aligned to our mission that will help maximize our impact and drive sustained change." Other steps the foundation has taken include identifying and developing opioid misuse and abuse initiatives that aim to redefine the best practices, further innovative ideas from the nonprofits, and improve the well-being of various communities. (Click for more...) Amazon is impacting independent pharmacies. Here's how they are fighting back. 12/7/2018 12:42:15 PM Amazon is impacting independent pharmacies. Here's how they are fighting back. Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 Significant changes are coming to the pharmacy industry, including CVS Health's $69 billion merger with Aetna, Cigna's $67 billion deal for Express Scripts, and the entrance of Amazon. Roger Paganelli, owner of Mt. Carmel Pharmacy in the Bronx, NY, is working to get health plans to pay him to enhance care for their patients via a group called the Community Pharmacy Enhanced Services Network. Under that arrangement, independent pharmacists help ensure that patients leaving the hospital receive the correct doses of their medications, and integrate their care with medical support outside the hospital. Mt. Carmel follows up with patients if they have not come in for a refill, for instance, and staff helps patients sync up their prescriptions so that they need to come in only once or twice. Similarly, the Community Pharmacy Enhanced Services Network (CPESN) seeks to help pharmacies reach deals with health plans to care for their patients. The group estimates that there are almost 2,000 pharmacies working under that type of arrangement. Troy Trygstad, PharmD, MBA, PhD, executive director of the CPESN, says the number of pharmacies in the network has been growing at a rate of about 100 pharmacies a month for the past 18 months. Meanwhile, the National Community Pharmacists Association estimates there were 22,041 independent pharmacies nationwide in 2016, down about 1,000 since 2011. (Click for more...) FDA's new strategic framework to advance use of real-world evidence to support development of drugs and biologics 12/7/2018 12:42:15 PM FDA's new strategic framework to advance use of real-world evidence to support development of drugs and biologics Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 The health care system is integrating more effective ways to leverage electronic tools to gather and use vast amounts of health-related data, according to FDA Commissioner Scott Gottlieb. These tools offer new opportunities to use data collected during the routine care of patients to advance medical care. Leveraging such real-world data (RWD) to improve regulatory decisions is a key strategic priority for FDA. on Thursday, the agency announced its new 2019 strategic framework for how it will continue to advance these opportunities. RWD collected from a variety of sources offer new opportunities to generate evidence and better understand clinical outcomes. These data are being used to develop information and real-world evidence (RWE) that can better inform regulatory decisions. RWD and RWE can be especially useful for postmarket monitoring of the safety of products during their use in real world settings. FDA is releasing a new, strategic, approach—the Framework for the Real-World Evidence Program, to apply across its drug and biologic review programs. This Framework is aimed at leveraging information gathered from patients and the medical community to inform and shape FDA's decisions across its drug and biologic development efforts. It will help FDA and industry evaluate the potential use of RWE to support regulatory decisions that have visible outcomes for consumers. (Click for more...) Decline stalls: 58 million Americans still exposed to secondhand smoke 12/7/2018 12:42:12 PM Decline stalls: 58 million Americans still exposed to secondhand smoke Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 Progress in reducing exposure to secondhand smoke among U.S. nonsmokers has stalled in recent years, despite longstanding declines over the past 30 years. An estimated 58 million American nonsmokers (1 in 4) were still exposed to secondhand smoke from burning tobacco products such as cigarettes during 2013–2014, according to new data published by CDC. Exposure to secondhand smoke remains high for certain groups, including children ages 3-11 years (38%), people living in poverty (48%), and people living in rental housing (39%), according to findings from the National Health and Nutrition Examination Survey. The study assessed exposure using serum cotinine, a marker of secondhand smoke found in the blood. "We know there’s no safe level of secondhand smoke exposure," said CDC Director Robert R. Redfield, MD. "These findings reveal that there is still much more to do to protect everyone—especially children—from this completely preventable health hazard." During 2011–2014, the percentage of nonsmokers exposed to secondhand smoke did not decline significantly across most demographic subgroups. This lack of decline could be attributable to the slowed adoption of comprehensive smoke-free laws in all workplaces, restaurants, and bars at the state and local levels during this period. Twenty-seven states and the District of Columbia have comprehensive smoke-free laws, but adoption of such laws has slowed in recent years. (Click for more...) Effects of fluoxetine on functional outcomes after acute stroke 12/7/2018 12:42:12 PM Effects of fluoxetine on functional outcomes after acute stroke Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 Researchers in the United Kingdom conducted the Fluoxetine Or Control Under Supervision (FOCUS) trial to examine if stroke patients would have improved functional outcomes with a 6-month course of fluoxetine compared with placebo. The trial, conducted at 103 U.K. hospitals, involved more than 3,100 adults with a clinical diagnosis of acute stroke with brain imaging compatible with intracerebral hemorrhage or ischemic stroke and had focal neurological deficits. Participants received oral fluoxetine 20 mg or placebo once daily for 6 months. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at the 6-month follow-up. The researchers used the simplified mRS questionnaire delivered by mail, supplemented by a telephone interview if necessary. The results of the trial indicate that fluoxetine 20 mg given daily for 6 months after an acute stroke did not significantly enhance patients' functional outcome or survival at 6 and 12 months. Researchers also found that the drug reduced the occurrence of depression but increased the risk for bone fractures at 6 months. More research needs to be conducted to determine additional benefits or harms, the authors concluded. (Click for more...) Efficacy and safety of a fatty acid amide hydrolase inhibitor in the treatment of cannabis withdrawal and dependence in men 12/7/2018 12:42:12 PM Efficacy and safety of a fatty acid amide hydrolase inhibitor in the treatment of cannabis withdrawal and dependence in men Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 New results from a randomized trial suggest that an experimental drug might help ease withdrawal symptoms in men with cannabis use disorder—but experts caution more research is needed. People with cannabis use disorder can experience cravings, withdrawal, and other issues. Researchers tested the efficacy and safety of the FAAH-inhibitor PF-04457845 in reduction of cannabis withdrawal and cannabis use in men who were daily cannabis users. In a study of 70 men, those who received the drug had fewer withdrawal symptoms and used less marijuana after 4 weeks than men on a placebo. The researchers concluded that PF-04457845, a novel FAAH inhibitor, reduced cannabis withdrawal symptoms and cannabis use in men, and might represent an effective and safe approach for the treatment of cannabis use disorder. (Click for more...) To their detriment, millions falsely think they are allergic to penicillin 12/7/2018 12:42:12 PM To their detriment, millions falsely think they are allergic to penicillin Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 Abbie Roth, a managing editor for Nationwide Children's Hospital publications in Columbus, Ohio, notes that more than 29 million people nationwide unnecessarily avoid taking penicillin antibiotics because they believe they are allergic. Although 10% of people in the United States report penicillin allergy, 90% are not actually allergic, CDC says. Some people may get a rash toward the end of a course of antibiotics, but it is most likely a adverse event of the medication or symptom of the disease rather than a true allergy. Once a penicillin allergy gets listed in a person's electronic health record, it can be difficult to find someone willing to remove it. Moreover, if a narrow-spectrum antibiotic such as penicillin cannot be taken, patients usually are prescribed a broad-spectrum antibiotic that is typically costlier, has more adverse events, may be less effective, and could contribute to antibiotic resistance. CDC estimates that at least 23,000 people in the United States die of a resistant infection annually. People who believe they are allergic to penicillin antibiotics should consult a physician to determine if they are truly allergic, which will enhance their health care and help curb antibiotic resistance. (Click for more...) Texans turn to hepatitis C buyers clubs to get life-saving medication 12/7/2018 12:42:12 PM Texans turn to hepatitis C buyers clubs to get life-saving medication Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 An increasing number of Americans are using international buyers' clubs to import generic hepatitis C medicine from abroad at a fraction of the cost. Buyers' clubs help patients purchase these drugs from India, where manufacturers are licensed to make low-cost generic versions for about 100 developing countries. The high price of the medicine in the United States has put it out of reach for the uninsured or those denied coverage. Uninsured Texans can apply for free hepatitis C drugs through patient assistance programs, but few people who used a buyers' club said they knew of that option. In addition, although Gilead Sciences announced it will begin selling generic versions of two hepatitis C drugs in the United States next year at a starting price of $24,000, the drugs are still often much less expensive overseas. Two clubs in Australia and one in the United Kingdom report helping more than 4,000 Americans import the medication for less than $2,500 a person. Health officials caution they cannot ensure the safety of foreign drugs bought online, but the regulations regarding those online purchases are unclear. Thus far, the clubs have not been shut down and few shipments have been stopped by U.S. officials. (Click for more...) Secretary Azar announces senior advisor for drug pricing reform 12/7/2018 12:42:12 PM Secretary Azar announces senior advisor for drug pricing reform Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 HHS Secretary Alex Azar on Thursday announced that John O’Brien, will serve as senior advisor to the Secretary for Drug Pricing Reform. Previously, O’Brien had served as advisor to the Secretary for Health Reform and Drug Pricing, as well as Deputy Assistant Secretary for Health Policy within the Office of the Assistant Secretary for Planning and Evaluation. Prior to his time at HHS, O’Brien, a pharmacist, was Vice President of Public Policy for CareFirst BlueCross BlueShield. He has also worked at the Centers for Medicare & Medicaid Services, the Notre Dame of Maryland University College of Pharmacy, and various pharmacy and pharmaceutical organizations. O’Brien has a master’s degree in public health from the Johns Hopkins Bloomberg School of Public Health, a doctor of pharmacy degree from Nova Southeastern University, and studied pharmacy and public policy at the University of Florida. (Click for more...) Congress to drug makers: Why stock buybacks over lowered drug prices? 12/7/2018 12:42:12 PM Congress to drug makers: Why stock buybacks over lowered drug prices? Thu, 12/06/2018 - 19:00 cbaker_admin Fri, 12/07/2018 - 12:42 Members of Congress are faulting drug manufacturers for using savings from last year's tax overhaul to buy back shares rather than lower prices. More than a dozen Democrats in the House of Representatives sent letters to five big pharmaceutical companies in October saying they had benefited from recent tax cuts but kept charging high prices. The letters singled out certain drugs whose list prices had increased and asked their manufacturers for details about price changes and the costs of research and advertising. Drug companies responded to the letters by saying they had used their tax savings in a variety of ways beyond share buybacks, such as boosting employee compensation, investing in U.S. facilities and making donations, while also cutting the prices of some drugs. The congressional scrutiny is the latest sign that drug pricing is emerging as a leading issue in Washington. Merging the tax overhaul with drug pricing gives Democrats, in particular, an opportunity to score points with voters. Multinational drug firms were big beneficiaries from the changes, because they generate a good portion of their sales outside the U.S. and had been keeping billions of dollars overseas to avoid having to pay U.S. taxes on the sums. (Click for more...) AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer 12/7/2018 11:00:09 AM AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat. On Friday, the company said the immunotherapy had failed to show it could extend the lives of head and neck cancer patients. (Click for more...) Tris Pharma recalls potentially harmful infants' ibuprofen 12/7/2018 10:16:54 AM Tris Pharma is recalling three lots of an infants' pain reliever it says contains potentially high levels of ibuprofen that could cause permanent kidney damage in some children. The recall comes after Tris was slapped this year with an FDA warning letter for its lack of urgency about investigating product failures. (Click for more...) With pricing outcry raging, U.S. drug spending grew less than 1% last year: CMS 12/7/2018 9:13:41 AM Congress and the Trump administration are riled up about drug prices and promising to drive them down. But a new government report shows that U.S. spending on retail pharmaceuticals grew less than half of 1% last year—far less than the rate in recent years. (Click for more...) AHA updates guidance on managing resistant hypertension 12/7/2018 8:58:52 AM AHA updates guidance on managing resistant hypertension Fri, 12/07/2018 - 09:07 ehaberkorn@aph… Fri, 12/07/2018 - 08:58 The American Heart Association (AHA) released an updated scientific statement on the detection, evaluation, and management of resistant hypertension, defined as an above goal BP despite the use of three antihypertensive drug classes or target BP levels after taking four or more antihypertensive medications. Resistant hypertension is estimated to occur in approximately 12% to 15% of the population and is associated with substantial morbidity and mortality. There-fore, a thorough understanding of potential precipitating factors and appropriate lifestyle and medical management is essential. (Click for more...) With Tesaro off the block, will Clovis be the next PARP maker to get swallowed up? 12/7/2018 8:27:57 AM Clovis, which markets PARP inhibitor Rubraca for ovarian cancer, has struggled to keep up with rivals like Tesaro's Zejula and AstraZeneca and Merck’s Lynparza. That's one of several challenges that have some biopharma experts speculating Clovis will be snapped up by an asset-hungry Big Pharma player. (Click for more...) FiercePharmaAsia—Takeda-Shire finish line; Sun’s crisis; J&J-Legend CAR-T 12/7/2018 8:21:56 AM The Takeda-Shire megamerger won go-aheads from shareholders; Sun Pharma plummets on reports of a potential government probe and governance issues; J&J and Legend update results from an early-stage myeloma trial testing their much-hyped CAR-T therapy; and more. (Click for more...) Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck 12/7/2018 7:03:28 AM Merck’s Keytruda finally has some immuno-oncology competition in first-line, non-small cell lung cancer, courtesy of Roche. But even with an FDA approval in the bag, the real test for Roche might still be to come. (Click for more...) Winners announced for the Medical & Scientific Excellence Awards! 12/7/2018 6:44:50 AM The winners of the PharmaTimes Medical & Scientific Excellence Awards have been announced – find out who took home the first batch of MSEA pharmas! (Click for more...) Mereo BioPharma and OncoMed propose merger 12/7/2018 5:46:36 AM The UK’s Mereo BioPharma is planning to merge with US group OncoMed Pharmaceuticals. (Click for more...) AZ’ Imfinzi fails in head and neck cancer trial 12/7/2018 5:09:45 AM AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). (Click for more...) Mallinckrodt to split business 12/7/2018 4:55:54 AM UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company (Click for more...) NICE OKs NHS funding for Gilead’s CAR T-cell therapy 12/7/2018 4:53:42 AM Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma. (Click for more...) 14.6% Sodium Chloride Concentrated Solution for Injection 12/6/2018 7:00:00 PM Drug: 14.6% Sodium Chloride Concentrated Solution for Injection, Revision Date: Fri, 07 Dec 2018 (Click for more...) Dexmedetomidine Hydrochloride 4 mcg/mL Premix for Injection 12/6/2018 7:00:00 PM Drug: Dexmedetomidine Hydrochloride 4 mcg/mL Premix for Injection, Revision Date: Fri, 07 Dec 2018 (Click for more...) Diltiazem Hydrochloride Injection 12/6/2018 7:00:00 PM Drug: Diltiazem Hydrochloride Injection, Revision Date: Fri, 07 Dec 2018 (Click for more...) Lorazepam Injection 12/6/2018 7:00:00 PM Drug: Lorazepam Injection, Revision Date: Fri, 07 Dec 2018 (Click for more...) Sodium Bicarbonate Injection 12/6/2018 7:00:00 PM Drug: Sodium Bicarbonate Injection, Revision Date: Fri, 07 Dec 2018 (Click for more...) Testosterone Enanthate Intramuscular Injection 12/6/2018 7:00:00 PM Drug: Testosterone Enanthate Intramuscular Injection, Revision Date: Fri, 07 Dec 2018 (Click for more...) Thrombin Topical Powder (Recombinant) 12/6/2018 7:00:00 PM Drug: Thrombin Topical Powder (Recombinant), Revision Date: Fri, 07 Dec 2018 (Click for more...) CMS's enhanced controls did not always prevent terminated drug utilization in Medicare Part D 12/6/2018 12:34:11 PM CMS's enhanced controls did not always prevent terminated drug utilization in Medicare Part D Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 HHS's Office of the Inspector General (OIG) reported recently that because the measures CMS has taken to deal with terminated drug utilization in Medicare Part D were not completely effective, CMS continued to accept some prescription drug event (PDE) data for terminated drugs in 2014 and 2015. The agency has taken steps to prevent terminated drug utilization in Part D; however, it accepted PDE data for more than $31 million in gross drug costs for 3,705 terminated drugs in those 2 years. OIG said that CMS did not compare the data on termination dates in its quarterly Medicaid drug rebate files with FDA's file, did not examine the discrepancies between the two data sources, and did not update its system edits in a timely fashion. OIG recommended "that CMS continue to strengthen its internal controls to ensure that all PDE data for terminated drugs are rejected by working with FDA to verify the accuracy of drug termination dates, to include comparing the information on termination dates in its two data sources, investigating discrepancies between the data sources, and verifying termination dates with the manufacturers; and by updating its system edits with a new version of FDA's file on a more timely basis." OIG added that while CMS agreed with the second recommendation, it does not "with our first recommendation, stating that although it remains committed to strengthening its internal controls to ensure that PDE data for terminated drugs are rejected, it regards FDA as the expert authority and source for national drug code listing information." (Click for more...) 41% of adults don't plan to get influenza vaccine despite last year's deadly season 12/6/2018 12:34:11 PM 41% of adults don't plan to get influenza vaccine despite last year's deadly season Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 As of mid-November, more than 40% of U.S. adults said they had not been vaccinated against influenza, nor did they plan to do so, according to a new survey from NORC at the University of Chicago. Many of those individuals expressed concern about adverse effects from the influenza vaccine or about contracting influenza from the vaccination. Others reasons for not getting vaccinated included that influenza vaccines were not very effective and that the individual did not expect to get sick from influenza. Health officials note that any adverse effects associated with the influenza vaccine are generally mild and the vaccine does not cause influenza. They also point to the high toll influenza took last year, with about 80,000 deaths in the United States. The survey noted that among adults with children younger than age 18 years, 39% said they do not vaccinate their children. In all, 43% of adults said they had been vaccinated against influenza and 14% more said they had not yet been vaccinated but plan to this season. The highest rate of influenza vaccination was among individuals older than age 60 years, while the lowest rates were among adults younger than age 45 years. The survey included about 1,200 interviews with a nationally representative sample of people in all 50 states and Washington, DC. (Click for more...) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma 12/6/2018 12:34:11 PM Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 Researchers conducted the ECHELON-2 trial to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas. For the study, 452 adults from 17 countries with previously untreated CD30-positive peripheral T-cell lymphomas were randomly assigned to receive either A+CHP or CHOP for six or eight 21-day cycles. Median progression-free survival—the primary endpoint—was 48.2 months in the A+CHP group and 20.8 months in the CHOP group. The groups saw similar adverse events, including the incidence and severity of febrile neutropenia and peripheral neuropathy. In all, seven patients (3%) in the A+CHP group and nine (4%) in the CHOP group suffered fatal adverse events. According to the authors, the findings indicate "that the addition of brentuximab vedotin to CHP resulted in higher rates of progression-free and overall survival without added toxicity and supports the potential for A+CHP to become a new standard of care for many patients with CD30-positive peripheral T-cell lymphoma." (Click for more...) AmerisourceBergen's study sees pharmacists playing a bigger role 12/6/2018 12:34:11 PM AmerisourceBergen's study sees pharmacists playing a bigger role Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 A new study from AmerisourceBergen finds that almost 80% of hospital pharmacists look forward to a greater role in health care and are well positioned to take on an expanded role. Streamlining prior authorization and reimbursement processes continues to be a challenge, and all pharmacy segments are focused on building stronger prescriber relationships to improve continuity and quality of care. "With their proximity to providers, shared access to electronic medical records, and strong commitment to outcomes, health system pharmacies are uniquely positioned to support clinically-integrated care," said Willis Chandler, president of Health Systems and Specialty Services at AmerisourceBergen. Hospital pharmacists in particular are spending more time on important coordination activities like communicating with health care providers, according to the survey. (Click for more...) Generic drug prices 'strongly predictive' of shortages, study finds 12/6/2018 12:34:11 PM Generic drug prices 'strongly predictive' of shortages, study finds Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 A new study published in Value in Health suggests that the price of a generic drug is a key factor in whether it undergoes a shortage. Generic drug prices "were strongly predictive of drug shortages," the researchers found after examining commonly used outpatient generic drugs from 2008 to 2014. They also found that the prevalence of shortages decreased from a peak in 2011–12 to less than 4% of the overall sample by the end of 2014. Competition and market size were not linked to the probability of a shortage, the authors from Harvard's Program on Regulation, Therapeutics, And Law and the University of Utah found. First author Chintan Dave believes pharmaceutical companies may be prioritizing "the continued production of more profitable products. Another hypothesis is that smaller profit margins may force manufacturers to cut corners in ways that compromise production quality, predisposing these products to further regulatory scrutiny and subsequent product disruptions." Complex formulations such as extended release capsules and solutions were also more likely to experience a shortage, according to Dave. He says FDA "should recognize that very low generic drug prices might be a factor in subsequent shortages and continue to consider the risk of shortages when taking steps to promote the safety and quality of the generic drug marketplace." (Click for more...) CVS Pharmacy completes rollout of time-delay safes in all KY pharmacy locations 12/6/2018 12:34:11 PM CVS Pharmacy completes rollout of time-delay safes in all KY pharmacy locations Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 Time-delay safes have been installed all 77 CVS Pharmacy locations in Kentucky, the company announced. The safes help deter thefts of controlled substance medications by electronically delaying the time it takes for pharmacy employees to be able to open the safes. CVS Pharmacy first implemented time-delay safes in Indianapolis in 2015, which led to a 70% decline in pharmacy thefts at those locations. All CVS Pharmacy locations with time-delay safes display prominent signage to inform the public that such safes are in use. CVS Health has also installed nine safe-medication disposal units in CVS stores in Kentucky. Nationwide, 750 safe-medication disposal units have been installed in CVS Pharmacy locations, and the company has committed to installing an additional 1,100 units in 2019. (Click for more...) CVS offers 'guaranteed net cost' for pharmacy benefit clients 12/6/2018 12:34:09 PM CVS offers 'guaranteed net cost' for pharmacy benefit clients Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 CVS Health on Wednesday said that as of January 1, it will offer a new prescription benefit option guaranteeing its health plan clients 100% of any rebates, discounts, or other fees paid by drug makers. The new plan model is aimed at providing greater drug cost simplicity, predictability, and transparency, according to company officials. The "guaranteed net cost" option could also deflect growing criticism that PBMs benefit from the widening gap between pharmaceutical list prices and their lower net cost after hefty rebates paid by drug makers to secure coverage and access to their products. PBMs such as CVS' Caremark unit make a profit by using their scale to negotiate drug prices and by providing cost-management strategies to health plans. Under its new option, CVS takes on the risk of drug price inflation and shifts in drug use. (Click for more...) Trastuzumab emtansine for residual invasive HER2-positive breast cancer 12/6/2018 12:34:09 PM Trastuzumab emtansine for residual invasive HER2-positive breast cancer Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 For women with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy with a trastuzumab-containing regimen, new research shows that the likelihood of recurrence of invasive breast cancer or death was significantly lower with adjuvant trastuzumab emtansine (T-DM1) compared with trastuzumab alone. An interim analysis of the Phase III, open-label KATHERINE trial found that invasive disease or death occurred in 12.2% (91 patients) in the T-DM1 group and 22.2% (165 patients) in the trastuzumab group. Additionally, the estimated percentage of patients who were free of invasive disease at 3 years was 88.3% in the T-DM1 group vs. 77.0% in the trastuzumab group. The data show that invasive disease-free survival was substantially higher in the T-DM1 group compared with the trastuzumab group, while distant recurrence as the first invasive-disease events occurred in 10.5 of the T-DM1 group and 15.9% of the trastuzumab group. A higher percentage of patients in the T-DM1 group experienced adverse events, which is consistent with the drug's known safety profile, compared with trastuzumab alone. (Click for more...) New drugs, decades in the making, are providing relief for migraines 12/6/2018 12:34:09 PM New drugs, decades in the making, are providing relief for migraines Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 Treatment for migraines has long addressed symptoms rather than prevention, and funding for research has been relatively low. But new treatments are giving patients more options to manage what is now considered a complex neurological disease. This year, FDA approved three drugs that aim to prevent migraines by targeting calcitonin gene-related peptide, the chemical involved in migraine. After years of treating migraines with medicine designed for other diseases, from blood pressure medication to antidepressants, experts say these new drugs are a significant step forward. "It is the first time we have a medication developed specifically for the mechanism of migraine, which means we are really targeting the disease state itself," said Susan Broner, medical director of the Headaches Program at Weill Cornell Medicine/New York-Presbyterian. Neurostimulation, which uses electrical stimulation to treat pain, is another option for patients that comes with the benefit of noninvasive or less invasive procedures. Although the complexity of migraines means no treatment is universal, what is important is that the condition now has a specific treatment, experts say. (Click for more...) UNM College of Pharmacy leading a coalition to focus on community pharmacies in underserved areas 12/6/2018 12:34:09 PM UNM College of Pharmacy leading a coalition to focus on community pharmacies in underserved areas Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 The University of New Mexico College of Pharmacy is joining with researchers from Minnesota and Massachusetts to create effective educational interventions for pharmacists through the CONsiDER project. The collaboration’s goal is to develop pharmacy-based interventions that are both universal and state-specific. "Pharmacists can make an acute impact within their communities," says Richard Larson, MD, PhD, executive vice chancellor for the UNM Health Sciences. "This project shows the power pharmacy research can have when it is embedded in an academic institution, pursuing all three of our missions of education, research and clinical care." The numerous routes in which people fall into opioid use disorder also complicate the situation. Current classification of opiates ranges from a variety of drugs ranging from legal drugs such as fentanyl, codeine, and morphine to illegal drugs such as heroin. It means health care professionals need educational materials that will be effective when speaking to people from a wide variety of backgrounds. The coalition’s agenda is ambitious and moving quickly. The CONsiDER team is starting this month to deliver training to identified pharmacies. "The quick pace the group has set for itself is good," Larson says. "We need to move fast in this rapidly changing situation." (Click for more...) Proportion of non-U.S.-born and noncitizen health care professionals in the U.S. 12/6/2018 12:34:09 PM Proportion of non-U.S.-born and noncitizen health care professionals in the U.S. Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 Approximately a fifth of U.S. pharmacists in 2016 were in another country, according to a recent study. Researchers examined data from the American Community Survey (ACS), an annual survey of U.S. households administered by the Census Bureau, to determine the proportion of current health care professionals in the country who are non-U.S.-born or noncitizens. The sample included 164,122 health care professionals, which represented 5.2% of the approximately 3 million ACS survey respondents in 2016. Of all U.S. health care professionals, 16.6% were non-U.S.-born and 4.6% were noncitizens. According to the survey, about 20% of pharmacists were born elsewhere, while nearly 4% were not citizens. In addition, about 29% of physicians were born elsewhere and almost 7% were not citizens, while the rates for dentists were about 24% and 4%, and for registered nurses were 16% and 3%, respectively. The findings show that "non–U.S.-born individuals and noncitizens comprised a significant proportion of many health care professions in 2016," the researchers write. They add that "as the US population ages, there will be an increased need for many health care professionals, particularly those who provide personal care like home health care aides, a large proportion of whom are currently non–U.S.-born." (Click for more...) Five trends shaping health system pharmacies next year 12/6/2018 12:34:09 PM Five trends shaping health system pharmacies next year Wed, 12/05/2018 - 19:00 cbaker_admin Thu, 12/06/2018 - 12:34 A new report from the McKesson RxO team lists five predictions for health system pharmacies in the coming year. First, spending on specialty drugs will increase. Specialty drugs currently represent about 45% of the pharmaceutical market spend in the United States. Hospitals have seen a 16% increase in the market, and there are no signs of it slowing in 2019, according to McKesson. The report also predicts that pharmacy services will continue being integrated into retail locations or stand-alone medical clinics. Additionally, pharmacists will be urged to continue monitoring drug spending and utilization next year. Other predictions include pharmacies increasing their focus on compliance as Congress considers changes to the 340B Drug Pricing Program as well as policies that describe how prescription drug prices are set to increase transparency. (Click for more...) Actelion inks $360M deal to resolve DOJ kickbacks probe 12/6/2018 12:16:01 PM Amid an industrywide probe of charitable contributions that has resulted in multimillion-dollar kickback settlements, Actelion is the latest to settle with the feds. (Click for more...) Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount 12/6/2018 11:22:51 AM Following an EpiPen generic launch by Teva, Novartis' Sandoz has released its launch plans for epinephrine alternative Symjepi. The drug will launch at a slight discount to Teva's product. (Click for more...) Troubled Mallinckrodt spins off specialty generics business in ongoing effort to reshape its image 12/6/2018 11:07:48 AM Mallinckrodt is forming two independent publicly traded companies in the hopes of improving the prospects for its branded specialty drugs, including its anti-inflammatory gel Acthar, which has been plagued by pricing controversies and lawsuits. (Click for more...) Big Pharma’s off-patent drugs lose out in China’s new price-cutting scheme 12/6/2018 10:41:28 AM In a Waterloo-style defeat, off-patent drugs from big pharma firms lost major markets in China as the government adopted a novel procurement scheme to slash generic drug costs. But after steep price cuts, local firms aren't considered winners, either. (Click for more...) Akorn fights to salvage Fresenius deal in appeal to Delaware Supreme Court 12/6/2018 10:33:27 AM Akorn, desperate to cling to its now-abandoned buyout by Fresenius, has taken its case for the deal to Delaware Supreme Court. Its argument? The lower court judge who said Fresenius bagged the deal legally didn't follow a legal standard in making that decision. (Click for more...) Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3 12/6/2018 9:45:05 AM With blockbuster Xolair aging, Novartis is looking to usher in a follow-up drug to keep that franchise growing, and it got one step closer this week. Armed with Xolair-topping phase 2 data, the Swiss drugmaker will push hives treatment candidate ligelizumab into phase 3. (Click for more...) Catalent is expanding and adding 36 jobs at its Indiana biologics plant 12/6/2018 9:44:02 AM Somerset, New Jersey-based CDMO Catalent says it has racked up 20 drug approvals for the Indiana biologics plant it picked up in its $950 million deal for Cook Pharmica last year. With that, Catalent says it needs to expand the facility and add workers. (Click for more...) Shire purchase backed by Takeda shareholders 12/6/2018 6:26:39 AM Takeda shareholders have backed the firm’s proposed £46 billion acquisition of Shire. (Click for more...) A third of doctors considering leaving clinical practice 12/6/2018 6:20:02 AM A new report from the General Medical Council (GMC) has found that a third of doctors are considering leaving medical practice, meaning they would no longer be working in clinical facing roles. (Click for more...) UCB to invest £1bn into UK under life sciences sector deal 12/6/2018 6:11:54 AM The government has published the second Life Sciences Sector Deal, detailing both public and private sector investments into the sector, including a £1 billion investment in UK research and development by UCB. (Click for more...) Norgine launches Shield’s Feraccru in the UK 12/6/2018 5:38:57 AM Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year. (Click for more...) First Alzheimer's drug from Eisai/UCL alliance to enter clinical trials 12/6/2018 5:13:48 AM The first drug candidate from Eisai and University College London (UCL)’s drug discovery collaboration is to enter Phase I clinical trials for Alzheimer’s disease (AD) early next year. (Click for more...) Roche’s Kadcyla cuts risk of breast cancer recurrence after surgery 12/6/2018 4:57:07 AM Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium. (Click for more...) Clinical Researcher of the Year - The Americas 2019 is open for entry with a category for everyone! 12/6/2018 3:03:19 AM The PharmaTimes Clinical Researcher of the Year – The Americas in association with MAGI has a broad range of categories to suit all types of clinical researcher. (Click for more...) Sanofi plots 670 layoffs in France as local tensions brew 12/5/2018 11:59:56 PM Sanofi may be on the up-and-up thanks to its vaccines unit and new anti-inflammatory star Dupixent, but the company still intends to shed more than 600 jobs in its home country over the next couple of years. (Click for more...) Azithromycin Injection 12/5/2018 7:00:00 PM Drug: Azithromycin Injection, Revision Date: Thu, 06 Dec 2018 (Click for more...) Cidofovir Injection 12/5/2018 7:00:00 PM Drug: Cidofovir Injection, Revision Date: Thu, 06 Dec 2018 (Click for more...) Flumazenil Injection 12/5/2018 7:00:00 PM Drug: Flumazenil Injection, Revision Date: Thu, 06 Dec 2018 (Click for more...) Leucovorin Calcium Injection 12/5/2018 7:00:00 PM Drug: Leucovorin Calcium Injection, Revision Date: Thu, 06 Dec 2018 (Click for more...) Lorazepam Tablets 12/5/2018 7:00:00 PM Drug: Lorazepam Tablets, Revision Date: Thu, 06 Dec 2018 (Click for more...) Metoprolol Injection 12/5/2018 7:00:00 PM Drug: Metoprolol Injection, Revision Date: Thu, 06 Dec 2018 (Click for more...) Midodrine Tablets 12/5/2018 7:00:00 PM Drug: Midodrine Tablets, Revision Date: Thu, 06 Dec 2018 (Click for more...) Mupirocin Calcium 2% Cream 12/5/2018 7:00:00 PM Drug: Mupirocin Calcium 2% Cream, Revision Date: Thu, 06 Dec 2018 (Click for more...) Mupirocin Calcium 2% Nasal Ointment 12/5/2018 7:00:00 PM Drug: Mupirocin Calcium 2% Nasal Ointment, Revision Date: Thu, 06 Dec 2018 (Click for more...) Roche's Tecentriq lines up for billion-dollar market with FDA priority tag 12/5/2018 6:13:19 PM Roche’s Tecentriq is closing in on a billion-dollar-plus lung cancer market that it can have all to itself. On Wednesday, U.S. regulators granted the immunotherapy a priority review in previously untreated patients with extensive-stage small cell lung cancer. (Click for more...) Novo keeps adding capacity, and jobs, to its North Carolina drug plant 12/5/2018 12:29:10 PM Just months after announcing a $65 million expansion that will boost capacity at the North Carolina facility where it makes diabetes drugs, Novo Nordisk says it needs yet more and will top it off with another $22 million and another 22 jobs. (Click for more...) Coalition proposes ways to combat drug shortages 12/5/2018 12:27:15 PM Coalition proposes ways to combat drug shortages Tue, 12/04/2018 - 19:00 cbaker_admin Wed, 12/05/2018 - 12:27 A coalition of health care groups is calling on the federal government to take steps to address the ongoing shortages of critical medications across the country. Among the groups that formulated the recommendations are the American Hospital Association, the American Society of Health-System Pharmacists, and the Institute for Safe Medication Practices. The coalition's 19 proposals were issued the day before a public meeting held by FDA and the Duke-Margolis Center for Health Policy that was designed to get stakeholder input on the root causes of drug shortages and what to do about them. The coalition recommends strategies that would allow health care providers to prepare for an imminent shortage of certain drugs. The group wants FDA to share information on the type of products that may be impacted during a public health emergency and the expected duration of the impact on the drug supply chain. These communications, the coalition says, would "allow health care organizations to assess their inventories ... and would give manufacturers the time needed to manage their supplies to ensure equitable distribution and guard against potential hoarding of drugs." The coalition also recommends that the Government Accountability Office be commissioned to report on the new and emerging factors that contribute to shortages. (Click for more...) GAO raises questions on FDA's orphan drug designation process 12/5/2018 12:27:14 PM GAO raises questions on FDA's orphan drug designation process Tue, 12/04/2018 - 19:00 cbaker_admin Wed, 12/05/2018 - 12:27 The Government Accountability Office (GAO) said it has discovered that FDA does not always ensure all information is consistently recorded and evaluated when making orphan drug designation determinations, suggesting that in some cases FDA reviewers do not fully understand the context of a drug's intended use for a particular rare disease. "The Commissioner of FDA should ensure that information from orphan drug designation applications is consistently recorded in OOPD [Office of Orphan Products Development] review templates and evaluated by OOPD reviewers when making an orphan designation decision," GAO recommended. The report follows an inquiry from lawmakers on potential abuses of the Orphan Drug Act. The analysis did not address such abuses, however, and focused more on the processes by which FDA evaluates orphan designation requests. Reviewers must record certain background information in a standard review template to inform their evaluation. Yet GAO's analysis of 148 designation review templates found that FDA reviewers did not include background data on the drug's U.S. marketing history in 48 of the templates and did not include the results of independent sources to verify the population estimate in 23 of them. HHS said the recommendation would be considered as part of FDA's efforts to improve the designation review template and to train reviewers. (Click for more...) Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa 12/5/2018 12:27:08 PM Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa Tue, 12/04/2018 - 19:00 cbaker_admin Wed, 12/05/2018 - 12:27 Although hydroxyurea effectively treats sickle cell anemia, its impact could be compromised in some parts of the world by malnutrition, malaria, and other coexisting conditions. To investigate, researchers enrolled more than 600 sub-Saharan children, aged 1–10 years, with the disease. Participants received hydroxyurea at a body weight-appropriate daily dose for 6 months, followed by dose escalation. The specified outcomes included feasibility, safety, and benefits. The therapy curbed the incidence of vaso-occlusive events, infections, malaria, transfusions, and death. In addition, dose-limiting toxic events regarding laboratory variables affected 5.1% of the study population, less than the protocol-specified threshold for safety. The evidence, showing daily hydroxyurea treatment to be safe and feasible in sub-Saharan children with sickle cell anemia, supports the need for expanded access to the therapy. As countries in the region launch newborn screening programs to detect sickle cell anemia, the researchers believe wider access to hydroxyurea may offer a simple and cheap oral medication that can alter the pathology of disease and prolong survival. (Click for more...) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer 12/5/2018 12:27:08 PM Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer Tue, 12/04/2018 - 19:00 cbaker_admin Wed, 12/05/2018 - 12:27 Researchers continue to pursue novel therapies to improve outcomes in patients with unresectable, triple-negative breast cancer. One potential approach entails using nanoparticle albumin-bound (nab)–paclitaxel to bolster the anti-tumor properties of another drug, atezolizumab. To flesh out the theory, investigators recruited about 900 breast cancer patients with untreated metastatic triple-negative disease for a Phase III clinical study. A total of 451 participants were randomized to receive nab-paclitaxel plus atezolizumab, and a like number were assigned to nab-paclitaxel plus placebo. The study identified dual primary outcomes: overall and progression-free survival. At followup a mean 12.9 months after intervention, progression-free survival was a median 7.2 months in the atezolizumab group vs. 5.5 months in the placebo group. Overall survival was a median 21.3 months and 17.6 months, respectively. The benefit of atezolizumab was also observed in a subset of patients with programmed death ligand 1-positive tumors. Those patients had overall and progression-free survival of 25 months and 7.5 months, respectively, compared with 15.5 months and 5 months for patients who received placebo plus nab-paclitaxel. Findings from the IMpassion130 clinical trial indicate that combination therapy with atezolizumab and nab-paclitaxel significantly prolongs progression-free survival in patients with metastatic triple-negative breast cancer without triggering additional safety concerns. (Click for more...) FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient care 12/5/2018 12:27:08 PM FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient care Tue, 12/04/2018 - 19:00 cbaker_admin Wed, 12/05/2018 - 12:27 FDA on Tuesday formally recognized a public database that includes information about genes, genetic variants, and their relationship to disease. The agency is recognizing the genetic variant information in the Clinical Genome Resource (ClinGen) consortium's ClinGen Expert Curated Human Genetic Data as a source of valid scientific information that can be used to support clinical validity in premarket submissions. "The availability of genetic tests is opening up new opportunities to segment illnesses into more treatable subsets and enabling the development of targeted therapeutics aimed at these previously unknown categories of disease," said FDA Commissioner Scott Gottlieb, MD. "These new medicines increasingly show outsized benefits in small populations of patients with rare, hard-to-treat and sometimes fatal conditions. The ability to use diagnostics to identify these rare subsets is a key element in driving this transformation in medical care and drug development." (Click for more...) Bipartisan senators introduce new drug pricing bill 12/5/2018 12:27:08 PM Bipartisan senators introduce new drug pricing bill Tue, 12/04/2018 - 19:00 cbaker_admin Wed, 12/05/2018 - 12:27 A bill introduced by Sens. Chuck Grassley (R-IA) and Ron Wyden (D-OR) attempts to crack down on any efforts by drug companies to overcharge taxpayers for Medicaid rebates. The bill would give HHS new authority to reclassify a drug and recoup rebates when a manufacturer deliberately misclassifies a drug in order to pay lower rebates. The lawmakers specifically mentioned Mylan, which paid $465 million to settle a lawsuit with the Justice Department in 2016. The company incorrectly classified the EpiPen as a generic drug, when it was actually a brand name drug. The settlement may have only been a fraction of the total amount Mylan underpaid. One federal analysis found that taxpayers may have overpaid for EpiPen by as much as $1.27 billion over 10 years. (Click for more...) Mylan expands nationwide voluntary recall of valsartan-containing products 12/5/2018 12:27:08 PM Mylan expands nationwide voluntary recall of valsartan-containing products Tue, 12/04/2018 - 19:00 cbaker_admin Wed, 12/05/2018 - 12:27 Mylan NV said it is expanding its consumer-level voluntary recall to include all lots of valsartan-containing products within expiry. The 104 additional lots are being recalled "out of an abundance of caution," Mylan said, after trace amounts of N-nitrosodiethylamine (NDEA), a probable cancer-causing impurity, were detected in the API valsartan. The batches were distributed in the United States between March 2017 and November 2018. The expanded recall includes 26 lots of amlodipine and valsartan tablets, USP (including the 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg, and 10 mg/320 mg strengths), 51 lots of valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and 27 lots of valsartan and hydrochlorothiazide tablets, USP (80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg strengths). (Click for more...) Association of oral anticoagulants and PPI cotherapy with hospitalization for upper GI tract bleeding 12/5/2018 12:27:08 PM Association of oral anticoagulants and PPI cotherapy with hospitalization for upper GI tract bleeding Tue, 12/04/2018 - 19:00 cbaker_admin Wed, 12/05/2018 - 12:27 New research from the Vanderbilt University School of Medicine looked at whether anticoagulant drug choice and proton pump inhibitor (PPI) cotherapy are associated with risk of upper gastrointestinal tract bleeding. The retrospective cohort study included 1.6 million Medicare beneficiaries with 1.7 million new episodes of oral anticoagulant treatment between 2011 and 2015. The adjusted incidence of hospitalization for upper gastrointestinal tract bleeding during 754,389 treatment person–years without PPI cotherapy was 115 per 10,000 person–years. The risk of hospitalization was highest for rivaroxaban and lowest for apixaban. When PPI therapy was added to anticoagulant treatment, the risk for hospitalization was lower overall and for each anticoagulant (apixaban, dabigatran, rivaroxaban, and warfarin). "These findings may inform assessment of risks and benefits when choosing anticoagulant agents," the authors conclude. (Click for more...) AstraZeneca's Calquence found success in lymphoma. Will CLL follow? 12/5/2018 10:39:27 AM Just over a year after approval, AstraZeneca’s Calquence is giving J&J and AbbVie’s Imbruvica a run for its money in mantle cell lymphoma. But the British drugmaker doesn’t want to stop there. It's eyeing a bigger market: chronic lymphocytic leukemia. (Click for more...) Taking aim at Medicaid misclassifications like Mylan's EpiPen, senators look to end a 'pharma ripoff' 12/5/2018 10:11:22 AM Two senators introduced a bill cracking down on drug misclassifications that cost Medicaid—and taxpayers—millions in underpaid rebates. In some cases, the rebates reach hundreds of millions: Mylan, for one, agreed to pay $465 million to settle allegations that it shorted Medicaid by calling EpiPen a generic. (Click for more...) Chinese drugmaker pours $145M into plant with plan to produce innovative biologics 12/5/2018 9:40:05 AM A Chinese maker of heparin and APIs for oncology and other drugs is launching the second phase of its manufacturing plant, investing nearly $150 million as it moves into producing innovative biologic drugs for the Chinese market. (Click for more...) New Vaccines Centre a ‘major commercial opportunity’ 12/5/2018 6:17:41 AM Business Secretary Greg Clark MP has announced the UK’s first dedicated Vaccines Manufacturing Innovation Centre (VMIC), said to represent a “major commercial opportunity”, and also a new front line in the nation’s defence against global pandemic threats. (Click for more...) Johnson & Johnson pays $300m to develop cusatuzumab 12/5/2018 6:10:23 AM Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies. (Click for more...) NHS to offer new non-invasive procedure for patients with faulty heart valve 12/5/2018 6:02:19 AM An innovative, non-invasive procedure to repair faulty valves in the heart has been approved by the National Institute for Health and Care Excellence for use on the NHS. (Click for more...) Mismanagement allegations send Sun Pharma stock tumbling: What we know so far 12/5/2018 2:56:23 AM Sun's top executive Dilip Shangvhi went into crisis mode Tuesday, tackling allegations of insider dealing and poor governance, not to mention reports that India's securities regulators would soon reopen an insider trading probe. But some key questions remain unanswered. (Click for more...) Sanofi merges biology and tech with research deal for digital asthma lab 12/4/2018 9:41:55 PM Sanofi plans to take asthma research where it has not gone before. A new partnership with Mount Sinai Health System and advanced analytics firm Sema4 will create a digital asthma laboratory. (Click for more...) Etomidate Injection 12/4/2018 7:00:00 PM Drug: Etomidate Injection, Revision Date: Wed, 05 Dec 2018 (Click for more...) As Amazon takes page from pharma's EHR playbook, smarter DTC could be on the way 12/4/2018 2:51:06 PM Amazon may be pushing for retail sales via EHRs, but it's just one move in its bigger strategic play around data and patients' electronic health records. (Click for more...) Solicitor general to back Merck at Supreme Court in Fosamax pre-emption case 12/4/2018 10:47:43 AM The solicitor general has been a major voice on pre-emption, generally backing the view that FDA decisions protect pharma from state legal challenges. Now, as the Supreme Court gears up for Merck's appeal in the Fosamax liability litigation, the feds are preparing to support the company's claim that pre-emption should protect it. (Click for more...) Ocular Therapeutix crosses finish line with eye treatment after running down production problems 12/4/2018 10:45:02 AM After twice being sidelined by manufacturing-related CRLs, Ocular Therapeutix got FDA approval on Monday for its first eye drug. The FDA nod came a month ahead of its latest PDUFA date after the eye specialist assembled a team to help it surmount FDA concerns over its production. (Click for more...) ASH: Johnson & Johnson, AbbVie's Imbruvica steals the CLL spotlight with phase 3 study wins 12/4/2018 10:15:03 AM Johnson & Johnson and AbbVie’s Imbruvica already competes in previously untreated chronic lymphocytic leukemia (CLL). But with some new head-to-head data against a "gold standard" regimen, the partners are looking to own it. (Click for more...) Study finds 1 in 4 patients can’t afford insulin 12/4/2018 9:41:39 AM Study finds 1 in 4 patients can’t afford insulin Tue, 12/04/2018 - 09:46 ehaberkorn@aph… Tue, 12/04/2018 - 09:41 It’s widely known at this point that patients with diabetes are skimping on insulin due to costs—but just how prevalent is it? Researchers of a new study published this month in JAMA Internal Medicine surveyed patients with type 1 and type 2 diabetes who had insulin prescribed to them within a 6-month window. (Click for more...) Could retroactive DIR fees become a thing of the past? 12/4/2018 9:31:12 AM Could retroactive DIR fees become a thing of the past? Tue, 12/04/2018 - 09:40 ehaberkorn@aph… Tue, 12/04/2018 - 09:31 APhA and other pharmacy groups hailed a CMS proposed rule that, if finalized, would pass drug price concessions directly to Medicare Advantage (MA) and Part D beneficiaries at the pharmacy counter. The proposed rule would account for pharmacy price concessions, also known as direct and indirect remuneration (DIR) fees, at the point of sale (POS). CMS projects this policy would reduce beneficiary out-of-pocket costs and improve price transparency and market competition under the Part D program. (Click for more...) Amazon takes first steps to expand PillPack online drug presence 12/4/2018 8:53:05 AM Amazon takes first steps to expand PillPack online drug presence Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 Amazon is expanding its efforts to launch online pharmacy operations by focusing on PillPack, which it acquired this past summer, according to analysts at investment banking firm Jefferies. Amazon is looking to acquire licenses for PillPack to operate in more states beyond the ones that PillPack had at the time of the acquisition, said Jefferies analysts. "Our proprietary check of (Amazon's) moves in the pharmacy space indicates that the online retailer has finally made moves to expand PillPack, though the initial expansion phase appears focused on offering pharmacy services to Amazon employees in WA," Jefferies indicated in a recent briefing. However, the license approval process is time-consuming, and other pieces to facilitate growth in pharmacy services are not yet in place, noted Jefferies' Brian Tanquilut. Amazon has secured a license for Washington state, and it has two pending license applications in New Mexico and Indiana. Jefferies research also found new job postings for pharmacy technician, packaging, and shipping linked to PillPack's Phoenix facility. PillPack currently has five mail-order prescription facilities, versus 26 run by Caremark, 18 from Optum, and 15 operated by Express Scripts. "We don't believe Amazon is currently in the position to rollout a full-scale 'Prime Rx' offering near-term … There's still a heavy lift required (in terms of building and acquiring additional distribution capacity) until PillPack can sufficiently service an extremely large membership base such as Prime," which it estimates to have 85 million members, the analysts said. (Click for more...) Federal judge voices concerns about DOJ approval of CVS-Aetna deal 12/4/2018 8:53:05 AM Federal judge voices concerns about DOJ approval of CVS-Aetna deal Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 Judge Richard Leon of the U.S. District Court for the District of Columbia, who has been tasked with signing off on the federal government's decision to approve CVS Health's acquisition of Aetna, indicated on Monday he may ask the two companies to halt integration pending his decision. Leon complained at a recent hearing that CVS and Aetna had been treating him as a "rubber stamp" for the $69 billion mega-deal. CVS closed the transaction a week ago and began the integration process. Leon said at a hearing on Monday that he would issue an order asking the two sides to argue why he should not require CVS and Aetna to be held separate until he decides whether he will approve the consent agreement reached in October between the companies and the U.S. Department of Justice (DOJ). Leon expressed concerns Monday that the DOJ had not adequately addressed the potential competitive harms raised by the merger. The judge remarked, "I am concerned that your complaint raises anti-competitive concerns about one-tenth of 1% of this $69 billion deal." (Click for more...) Virginia moves to limit mail-order specialty pharmacies 12/4/2018 8:53:05 AM Virginia moves to limit mail-order specialty pharmacies Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 Mail-order specialty pharmacies are growing in popularity, but Virginia regulators are seeking more control over deliveries from these businesses. Recently, Virginia's Board of Pharmacy gave initial approval to several changes, including requiring delivering pharmacies to inform hospitals and doctors' offices of the expected arrival time and storage instructions for medicines, banning the delivery of products requiring special storage directly to the patient's home, and mandating that the specialty pharmacy provide a return procedure for items that are not delivered. Delivering the medicine from the specialty pharmacy to either a practitioner's office or a patient's home can save prescribers costs associated with purchasing and stocking medicine, according to a study published by the National Association of Boards of Pharmacy (NABP). However, although the model has some benefits, NABP and other health care providers have expressed concern about the potential dangers for patients, potential waste, and the unclear responsibility when something goes wrong with a delivery. "For the most part, this practice is being driven solely for the financial benefit of insurance vendors, not for the benefit (or safety) of the patient or health care provider," said Cynthia Williams of Newport News-based Riverside Health System. The proposed regulations will be subject to a 60-day comment period before the Board of Pharmacy holds an official vote, which would send them to Gov. Ralph Northam of Virginia for final approval. (Click for more...) Chains urge influenza shots during National Influenza Vaccination Week 12/4/2018 8:53:03 AM Chains urge influenza shots during National Influenza Vaccination Week Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 In recognition of National Influenza Vaccination Week, which runs from December 2–8, CVS Health and Rite Aid are encouraging patients to drop in for influenza vaccination, if they have not already done so. "Flu levels are typically at their highest between December and February, and while we are seeing an increased number of vaccinations this year, it's important to remind those who have not yet gotten vaccinated that there is still time to do so," said Papatya Tankut, CVS Health vice president of pharmacy affairs. "With the flu typically spreading to many communities this time of year and people gathering for the holidays, it is especially important for families to get vaccinated to ensure they remain healthy through the holiday season and into 2019." Rite Aid also pointed to the CDC recommendation that most healthy Americans aged 6 months or older, including pregnant women, get vaccinated against influenza. "When it comes to the flu, prevention is better than treatment, and our more than 6,000 Rite Aid certified immunizing pharmacists stand ready to help people protect themselves from the flu this year," noted Jocelyn Konrad, Rite Aid executive vice president of pharmacy. "When you get a flu shot, you're not only protecting yourself, you're also helping to protect the others around you from getting the flu." (Click for more...) McKesson announces new global headquarters in Las Colinas, Texas 12/4/2018 8:53:03 AM McKesson announces new global headquarters in Las Colinas, Texas Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 McKesson Corp. announced that it will relocate its corporate headquarters to Las Colinas, TX, from San Francisco, effective April 1, 2019. The Las Colinas location is already a key site for McKesson, with employees there involved in operations, information technology, finance and accounting, marketing and sales, administration and support, purchasing, and project management. "We are excited to strengthen our presence in Texas and make Las Colinas our official global headquarters," said John Hammergren, chairman and CEO, McKesson Corp. "Gov. Abbott and the Irving/Las Colinas community have provided tremendous support since we opened our Las Colinas campus last April. Making this move will improve efficiency, collaboration and cost-competitiveness, while providing an exceptional work environment for our employees." McKesson will still have a strong presence in California after the move, employing more than 1,400 personnel, primarily in distribution operations and sales. In April, McKesson announced a multi-year strategic growth plan. As part of that initiative, said Brian Tyler, president and COO, "we've developed a hub location strategy, co-locating people based on the type of work they do to improve teamwork, advance innovation and increase efficiency. Bringing employee groups together in key locations will make McKesson a more streamlined and agile company, complementing our investments and improving operating profit growth for the organization." (Click for more...) Under Trump, number of uninsured kids rose for first time this decade 12/4/2018 8:53:03 AM Under Trump, number of uninsured kids rose for first time this decade Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 The number of U.S. children without health insurance rose to 5% (3.9 million) last year—up from 4.7% (3.6 million) in 2016, according to a new Georgetown University analysis of Census data. Although not a big jump statistically, the numbers are striking given that the uninsured rate typically remains stable or falls during times of economic growth. "The nation is going backwards on insuring kids and it is likely to get worse," said Joan Alker, coauthor of the study and executive director of Georgetown's Center for Children and Families. Alker and other child health advocates attribute this change to the Trump administration and the Republican-controlled Congress, saying their policies and actions have affected enrollment. The overall uninsured rate for people of all ages, which declined from 2013 to 2016 following the health law's implementation, remained steady at 8.8% in 2017. The uninsured rates for children rose at nearly three times the rates in states that did not expand Medicaid under the Affordable Care Act, according to the report. Studies have shown that children whose parents are insured are more likely to have coverage. Because almost all low-income children are eligible for Medicaid or the federal Children's Health Insurance Program, Alker stressed the importance of making sure parents are aware of the programs, getting them enrolled, and keeping them signed up. (Click for more...) Study suggests empagliflozin improves heart structure 12/4/2018 8:53:02 AM Study suggests empagliflozin improves heart structure Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 Empagliflozin has important effects that can improve cardiac structure in people with type 2 diabetes who also have heart disease, according to new research from researchers at St. Michael's Hospital in Toronto. The EMPA-HEART CardioLink-6 trial examined the effect of empagliflozin on the structure and function of the left ventricle in people with type 2 diabetes and a history of cardiovascular disease, using MRI testing over a 6-month period. C. David Mazer, MD, part of the EMPA-HEART team, says the findings "provide important clues as to how this medication is working, and how it may prevent heart failure in people with type 2 diabetes." The findings were presented at the American Heart Association meeting in Chicago. (Click for more...) Kroger to sell groceries in Walgreens stores 12/4/2018 8:53:02 AM Kroger to sell groceries in Walgreens stores Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 Kroger plans to sell groceries in branded sections of Walgreens Boots Alliance stores, as both companies look for ways to keep customers loyal to their products. The first "Kroger Express" sections will open by early 2019 in 13 Walgreens stores. The companies say they will add more of the 4,000-square-foot displays if customers take to them. They will account for about 33% of an average Walgreens selling space. Kroger and Walgreens executives have not said how the companies will share sales revenue or provided financial details of the deal. Kroger and Walgreens will supply and operate the Kroger-branded sections together, officials say. (Click for more...) Association of opioid prescriptions from dental clinicians for adolescents and young adults with subsequent opioid use and abuse 12/4/2018 8:53:00 AM Association of opioid prescriptions from dental clinicians for adolescents and young adults with subsequent opioid use and abuse Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 New research suggests that many adolescents and young adults are exposed to opioids through dental clinicians. The retrospective cohort study, which looked at claims data for individuals aged 16–25 years, found that 12.9% of about 754,000 patients with continuous enrollment in 2015 received one or more opioid prescriptions that year. Of those patients, 30.6% (29,791) received prescriptions supplied by a dental clinician. The index dental opioid cohort—created after excluding for previous complex chronic conditions, hospitalizations in the past week, and opioid prescriptions or diagnoses of opioid abuse with a year of the index opioid prescription—included 14,888 individuals. In that group, 6.9% received another opioid prescription 90–365 days later, vs. 0.1% of 29,776 opioid-nonexposed controls. Additionally, 5.8% of the index dental opioid group experienced one or more subsequent health care encounter with an opioid abuse-related diagnosis, compared with 0.4% of the opioid-nonexposed controls. "The findings of our study suggest that opioid-naive patients who receive an opioid prescription from a dental clinician may be at risk for persistent opioid use and abuse," the researchers conclude. "Given the potential contribution of third molar extractions to the opioid epidemic, heightened scrutiny regarding this procedure and opioid prescriptions associated with postoperative care is warranted." (Click for more...) Ibrutinib regimens vs. chemoimmunotherapy in older patients with untreated CLL 12/4/2018 8:53:00 AM Ibrutinib regimens vs. chemoimmunotherapy in older patients with untreated CLL Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:53 Phase III testing sought to compare the effect of ibrutinib vs. chemotherapy in older patients with untreated chronic lymphocytic leukemia (CLL). Researchers recruited 547 Americans and Canadians aged 65 years and older for their sample population. A total of 183 study participants were randomized to receive six cycles of standard chemoimmunotherapy with bendamustine plus rituximab. A group of 182 patients was assigned to daily ibrutinib alone, while a third treatment arm, also including 182 patients, received continuous ibrutinib plus rituximab. The primary outcome was progression-free survival, which came in at a rate of 74% after 2 years in the bendamustine group. For the ibrutinib patients, by comparison, the rate was 87% for monotherapy and 88% for the combination therapy, proving ibrutinib to be the superior approach. Ibrutinib therapy also produced a lower rate of hematologic adverse events rated at grades 3, 4, or 5 than bendamustine plus rituximab. Grade 3 and higher nonhematologic adverse events, however, were less likely with bendamustine plus rituximab than with ibrutinib. The secondary endpoint of overall survival, meanwhile, was comparable for all three treatment arms. (Click for more...) CDC: AFM cases appear to have peaked for the year 12/4/2018 8:52:57 AM CDC: AFM cases appear to have peaked for the year Mon, 12/03/2018 - 19:00 cbaker_admin Tue, 12/04/2018 - 08:52 Federal health officials reported Monday that the number of cases under investigation for acute flaccid myelitis (AFM) appears to have peaked for 2018 and will continue to decline for the rest of the year. According to CDC, 134 cases of AFM have been confirmed in 33 states out of 299 reported cases this year. CDC noted that figure is up 18 confirmed cases from the previous week; however, the majority of the most recent confirmed cases occurred in September and October. The agency said it has seen a pattern of higher numbers of confirmed AFM cases every 2 years, with about 120 cases in 2014, 22 in 2015, 149 in 2016, and 33 last year. Fewer cases are expected in the coming months, but CDC said it will continue to carefully study and monitor the condition in order to better diagnose and treat it going forward. (Click for more...) Researchers at LegoChem Biosciences Share How Information Solutions Power Their Innovative Work 12/4/2018 5:07:53 AM With its groundbreaking work in developing antibody-drug conjugates, antibiotics, anti-coagulants and anti-cancer therapies, LegoChem Biosciences was already doing important research before joining The Hive. But the advantage of being a part of the Hive program – which gives specially-selected participants access to Elsevier’s R&D solutions – has been to help this innovative company accelerate and […] (Click for more...) Buprenorphine Hydrochloride Injection 12/3/2018 7:00:00 PM Drug: Buprenorphine Hydrochloride Injection, Revision Date: Tue, 04 Dec 2018 (Click for more...) Carbidopa and Levodopa Extended-Release Tablets 12/3/2018 7:00:00 PM Drug: Carbidopa and Levodopa Extended-Release Tablets, Revision Date: Tue, 04 Dec 2018 (Click for more...) Diltiazem Extended-Release Capsules (Twice-Daily Dosing) 12/3/2018 7:00:00 PM Drug: Diltiazem Extended-Release Capsules (Twice-Daily Dosing), Revision Date: Tue, 04 Dec 2018 (Click for more...) Indomethacin Capsules 12/3/2018 7:00:00 PM Drug: Indomethacin Capsules, Revision Date: Tue, 04 Dec 2018 (Click for more...) Ketamine Injection 12/3/2018 7:00:00 PM Drug: Ketamine Injection, Revision Date: Tue, 04 Dec 2018 (Click for more...) Morphine PCA Vials 12/3/2018 7:00:00 PM Drug: Morphine PCA Vials, Revision Date: Tue, 04 Dec 2018 (Click for more...) Mycophenolate Mofetil Capsules and Tablets 12/3/2018 7:00:00 PM Drug: Mycophenolate Mofetil Capsules and Tablets, Revision Date: Tue, 04 Dec 2018 (Click for more...) Remifentanil Injection 12/3/2018 7:00:00 PM Drug: Remifentanil Injection, Revision Date: Tue, 04 Dec 2018 (Click for more...) Trifluoperazine Tablets 12/3/2018 7:00:00 PM Drug: Trifluoperazine Tablets, Revision Date: Tue, 04 Dec 2018 (Click for more...) SMART therapy associated with a lower risk of asthma exacerbations 12/3/2018 11:59:46 AM Key Point:A meta-analysis of 16 trials evaluating use of a single maintenance and reliever therapy (SMART), with the majority of studies using a combination of budesonide and formoterol in a dry-powder inhaler, found that the risk of asthma exacerbations was lower in patients using this regimen compared with an inhaled corticosteroid (ICS) as the controller therapy (with or without a long-acting beta-agonist [LABA]) plus a short-acting beta-agonist (SABA) as the relief therapy. (Click for more...) Switching antiepileptic suppliers associated with increased seizure risk? 12/3/2018 11:06:11 AM Key Point:Switching the manufacturer of antiepileptic drugs increased the risk of seizure recurrence in patients who were previously seizure-free, according to a retrospective, observational study published in the Annals of Neurology. (Click for more...) SIDP calls on pharmacists to lead outpatient antibiotic stewardship 12/3/2018 8:55:09 AM SIDP calls on pharmacists to lead outpatient antibiotic stewardship Mon, 12/03/2018 - 09:01 ehaberkorn@aph… Mon, 12/03/2018 - 08:55 The Essential Role of Pharmacists in Antibiotic Stewardship in Outpatient Care, a recent position statement published by the Society of Infectious Disease Pharmacists (SIDP), underscores the impact of pharmacy involvement on infection prevention and control. In the face of rapidly evolving regulations, SIDP called upon pharmacists as leaders to design and implement strategies for antibiotic stewardship in outpatient settings. (Click for more...) FDA takes steps to advance the safety and accuracy of blood glucose monitors 12/3/2018 5:45:10 AM FDA takes steps to advance the safety and accuracy of blood glucose monitors Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 FDA on Thursday issued two revised draft guidances regarding blood glucose monitors used in health care and home settings: Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use and Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use. These new draft guidances, when finalized, will update two final guidances issued in 2016. The changes are based on additional feedback from stakeholders requesting more clarification on design considerations and recommended standards. The action is part of the agency's efforts to improve the development of new blood glucose meters based on feedback from both patients and health care providers, especially on the usability of glucose monitors. The two draft guidances provide recommendations to industry about the types of information to be included in their premarket submissions for these devices. FDA is seeking comments on the revised draft guidances. These revisions do not change the recommended studies, the performance goals, or the pathway to obtaining Clinical Laboratory Improvement Amendments waiver for these devices. (Click for more...) Sen. Jeff Merkley introduces bill to lower prescription drug prices 12/3/2018 5:45:10 AM Sen. Jeff Merkley introduces bill to lower prescription drug prices Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 Sen. Jeff Merkley (D-OR) introduced legislation on Thursday that would prevent drug manufacturers to access federal health programs such as Medicare for any drug that exceeds the median price charged in 11 reference countries. Shortly before the November elections, the Trump administration floated the idea of issuing a new regulation to bring Medicare prescription costs in line with international price levels, but the proposal faces stiff opposition from the conservative movement and congressional Republicans. Democrats made lowering prescription drug prices a central plank of the party’s national message during the midterm campaigns, and lawmakers are now sorting out exactly how they plan to deliver on that promise. Sen. Bernie Sanders (I-VT) and Rep. Ro Khanna (D-CA.) introduced a separate bill taking aim at drug prices earlier this month. None of this Democratic legislation is likely to be enacted so long as Republicans control the Senate, but it serves as a focal point for debate in Washington. "It's a long way from the introduction of a bill to the enactment of a law, but ideas start someplace," says David Mitchell, founder of Patients for Affordable Drugs NOW, a nonprofit devoted to lowering prescription drug prices. (Click for more...) FDA warns company for selling e-liquids that resemble kid-friendly foods 12/3/2018 5:45:10 AM FDA warns company for selling e-liquids that resemble kid-friendly foods Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 FDA on Thursday issued a warning letter to Electric Lotus LLC for selling nicotine-containing e-liquids used in e-cigarettes with labeling and/or advertising that cause them to resemble kid-friendly food products, such as cereal, candy, and peanut butter and jelly. The action is part of the agency’s ongoing effort to protect kids from tobacco products. Electric Lotus—a manufacturer, distributor, and retailer, based in Redlands, California—was also cited for illegally selling products to a minor, for failing to list its products with FDA, and for selling e-liquids without the required FDA premarket authorization. All of the products identified in the warning letter are adulterated and misbranded because they do not have required FDA premarket authorization. FDA has requested that the company respond within 15 working days to describe how it intends to address the agency's concerns. Failure to correct violations may result in further action such as seizure or injunction. In addition, misbranded or adulterated products imported into the United States are subject to detention and refusal of admission. This new warning letter is part of series of actions over the past several months to address an epidemic growth in the use of e-cigarettes by children and disturbing evidence of illegal sales of e-cigarettes to youth. These actions include steps to target the kid-friendly marketing and appeal of these products. (Click for more...) FDA spotlights recent spike in drug shortages 12/3/2018 5:45:07 AM FDA spotlights recent spike in drug shortages Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 Matthew Rosenberg, an economics staffer at FDA, recently examined the extent of drug shortages based on FDA archives and the IQVIA national sales database. He found that ongoing shortages have become more prevalent over the last year or so, and in terms of duration there are more persistent shortages now than was previously the case. In terms of intensity, more than two-thirds of historical volumes have typically been unavailable for these drugs. FDA Commissioner Scott Gottlieb notes that many of the critical drugs in shortage are sterile injectable drugs, and most of these drugs are longtime, generic medicines that are relatively inexpensive. Experts add that buyer and seller consolidation, along with low margins and contracting practices, can contribute to drug shortages. There are also markets where the prices may be too low to sustain reliable supply and the necessary investments in manufacturing, according to Gottlieb. The Association for Accessible Medicines points out that FDA can influence changes around improving the existing expedited resolution pathway for drugs in shortage. "AAM believes FDA should permit generic sponsors to comply with new or updated standards as a post-market commitment to mitigate delays in access," AAM said. "New cGMP requirements and or enhancements to cGMP requirements should be provided via guidance rather than via 483s or warning letters." (Click for more...) Juul's new product: Less nicotine, more intense vapor 12/3/2018 5:45:07 AM Juul's new product: Less nicotine, more intense vapor Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 In an effort to lower the nicotine in its e-cigarette pods, Juul Labs is seeking to increase the pods' vapor. However, experts say doing so can raise the rate at which nicotine is absorbed in the body. Sources say the company hopes the higher vapor pods will appeal to cigarette smokers who are accustomed to a larger cloud, while reducing the nicotine level to meet stricter nicotine limits in many countries. In the European Union, where Juul plans to expand, for instance, the nicotine limit for e-cigarettes is 20 mg per ml of fluid—about a third of the amount in the most popular American Juul pod. A lower nicotine version is also on sale in the United States at 23 mg of nicotine per ml of fluid. Juul has not ruled out marketing the new product in the United States but would need FDA's approval to do so. FDA Commissioner Scott Gottlieb has encouraged the development of alternatives such as e-cigarettes and, early in his tenure, extended the deadline for them to meet strict new agency rules. FDA also hopes to reduce nicotine to nonaddictive levels in conventional cigarettes. The agency has started that process, but tobacco firms are preparing to resist. The agency has yet to announce setting limits on nicotine in e-cigarettes. (Click for more...) Drug cost containment strategies for hospital pharmacy leaders highlighted at ASHP Midyear 12/3/2018 5:45:07 AM Drug cost containment strategies for hospital pharmacy leaders highlighted at ASHP Midyear Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 At the 2018 American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting, Cardinal Health will highlight a comprehensive approach that addresses the top concern of hospital and health system pharmacy leaders: sustainable cost control. By taking this comprehensive approach, hospital pharmacies can achieve savings of 5% or more, year-after-year, says Kathy Chase, director of Drug Cost Control Services at Cardinal Health. "The role of the pharmacy is uniquely positioned to support the call of health systems to discover savings, boost efficiencies, and promote high-quality patient care." Key steps to Cardinal Health's approach will be showcased during the ASHP Midyear Meeting, including the implementation of an RFID-enabled consignment model for inventory optimization, as well as leveraging and optimizing patient assistance programs. "The need to identify innovative approaches to control costs and increase quality and outcomes will continue to be a focus as specialty drug spend continues to outpace traditional drug spend," says John Kilgour, vice president of acute and alternate care sales for Specialty Pharmaceutical Distribution at Cardinal Health. "With a consignment model, pharmacies can free up dollars tied up in inventory by only paying for these unique products once they are used." The ASHP Midyear Clinical Meeting will take place December 2-6 in Anaheim, CA. (Click for more...) A superbug needs to be stopped. A Glaxo vaccine may slow it down 12/3/2018 5:45:05 AM A superbug needs to be stopped. A Glaxo vaccine may slow it down Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 Cases of gonorrhea are rising in New Zealand, which is examining ways to slow down the spread of the sexually transmitted disease. One way could be using a vaccine already on the market against meningococcal bacterium. Gonorrhea is becoming increasingly antibiotic resistant and some strains are behaving like related infections that persist in the throat, making transmission easier, physicians say. Helen Petousis-Harris, PhD, a vaccinologist at the University of Auckland, worked with colleagues to show that a custom-made meningococcal B vaccination was associated with protection against gonorrhea. Her paper published in Lancet estimated that vaccination against meningococcal B resulted in 31% effectiveness against gonorrhea. GlaxoSmithKline has not yet made a decision on whether to target gonorrhea with serogroup B meningococcal vaccine (Bexsero-GlaxoSmithKline), which is predicted to generate $780 million in sales this year as a strictly meningococcal B vaccine. The product has a retail price in the United States of about $166 per dose. The bacterial causes of meningococcal disease and gonorrhea share 80% to 90% of their DNA, and results of studies using animal models support the use of serogroup B meningococcal vaccine for controlling gonorrhea. However, gauging success would be difficult because there is no known way to determine protection against gonorrhea in humans, notes Charlene Kahler, PhD, head of infection and immunity at the University of Western Australia’s School of Biomedical Sciences in Perth. (Click for more...) Alirocumab and cardiovascular outcomes after acute coronary syndrome 12/3/2018 5:45:03 AM Alirocumab and cardiovascular outcomes after acute coronary syndrome Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 The randomized, multisite ODYSSEY OUTCOMES clinical trial examined the effect of alirocumab on cardiovascular outcomes within a year after an acute coronary syndrome. Study participants, all of whom were receiving high-intensity statin therapy, received either subcutaneous alirocumab or matching placebo every 2 weeks. Each treatment arm included 9,462 patients. The main endpoint was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Followup at a mean 2.8 years found that 9.5% of the alirocumab group and 11.1% of the controls had suffered a composite primary endpoint event, with mortality rates of 3.5% and 4.1%, respectively. The researchers concluded that, compared with placebo, alirocumab reduces the risk of recurrent ischemic cardiovascular events after an acute coronary syndrome in patients receiving high-intensity statin therapy. (Click for more...) Congo Ebola outbreak is 2nd largest, 2nd deadliest 12/3/2018 5:45:03 AM Congo Ebola outbreak is 2nd largest, 2nd deadliest Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 The current Ebola epidemic in the Democratic Republic of Congo has experienced 426 total cases, including 245 deaths, making it the second largest and second deadliest in history, according to Thursday's report from the nation's Ministry of Health. The deadliest outbreak occurred in West Africa in 2014, when the disease killed more than 11,000 people. This is the 10th outbreak since 1976 in Congo, where the virus is endemic, and the second this year. "The risk of the outbreak spreading to other provinces in the Democratic Republic of the Congo, as well as to neighboring countries, remains very high," the World Health Organization (WHO) said in a statement Thursday. However, there have been no confirmed cases in Congo's neighbors, said WHO spokesman Tarik Jasarevic. "All neighboring countries have implemented heightened surveillance, and are detecting and investigating alerts and suspected Ebola cases." In October, CDC personnel who had been stationed in Congo had been pulled back from the worst affected areas due to safety concerns. A Congo government report indicates that 37,559 people have received an experimental vaccine in a campaign that began August 8. "This includes over 11,100 health and frontline workers, and 9,300 children," Jasarevic said. The experimental rVSV-ZEBOV vaccine, made by Merck, proved highly protective against the deadly virus in a major trial in Guinea, according to WHO. (Click for more...) FDA approves first treatment for Lambert-Eaton myasthenic syndrome 12/3/2018 5:45:03 AM FDA approves first treatment for Lambert-Eaton myasthenic syndrome Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 FDA has approved amifampridine (Firdapse—Catalyst Pharmaceuticals) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS. "There has been a long-standing need for a treatment for this rare disorder," said Billy Dunn, MD, director of the Division of Neurology Products in FDA's Center for Drug Evaluation and Research. "Patients with LEMS have significant weakness and fatigue that can often cause great difficulties with daily activities." The efficacy of amifampridine was studied in two clinical trials that together included 64 adult patients who received amifampridine or placebo. The studies measured the Quantitative Myasthenia Gravis score (a 13-item physician-rated categorical scale assessing muscle weakness) and the Subject Global Impression (a seven-point scale on which patients rated their overall impression of the effects of the study treatment on their physical well-being). For both measures, the patients receiving amifampridine experienced a greater benefit than those on placebo. The most common adverse events experienced by patients in the clinical trials were burning or prickling sensation (paresthesia), upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension and muscle spasms. Seizures have been observed in patients without a history of seizures. (Click for more...) HHS implements long-awaited 340B drug price transparency rule 12/3/2018 5:45:01 AM HHS implements long-awaited 340B drug price transparency rule Thu, 11/29/2018 - 19:00 cbaker_admin Mon, 12/03/2018 - 05:45 HHS on Thursday announced it will implement the long-delayed final rule for enforcing 340B drug ceiling price transparency on January 1, 2019. Enforcement will be maintained through a closed website available to 340B participating hospitals and providers. Federal regulators will post drug pricing information on the site. The decision ends five delays over 8 years since Congress gave HHS the ability to enforce drug price ceilings. HHS officials said the delays were made to conduct longer rulemaking. Essential Hospitals said the regulator's decision to finally implement the rule was the result of a lawsuit it and six other stakeholders, including the American Hospital Association, brought against the agency in September over the delay. "The final rule issued by HHS and the Health Resources and Services Administration is a big step toward stopping drug companies from overcharging 340B hospitals, clinics, and health centers," said Maureen Testoni, interim president and CEO of 340B Health. (Click for more...) Alpha-1 Proteinase Inhibitor 12/2/2018 7:00:00 PM Drug: Alpha-1 Proteinase Inhibitor, Revision Date: Mon, 03 Dec 2018 (Click for more...) Amino Acid Products 12/2/2018 7:00:00 PM Drug: Amino Acid Products, Revision Date: Mon, 03 Dec 2018 (Click for more...) Asparaginase Erwinia chrysanthemi 12/2/2018 7:00:00 PM Drug: Asparaginase Erwinia chrysanthemi, Revision Date: Mon, 03 Dec 2018 (Click for more...) Atenolol and Chlorthalidone Tablets 12/2/2018 7:00:00 PM Drug: Atenolol and Chlorthalidone Tablets, Revision Date: Mon, 03 Dec 2018 (Click for more...) Cefotaxime Sodium Injection 12/2/2018 7:00:00 PM Drug: Cefotaxime Sodium Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Ceftriaxone Sodium Injection 12/2/2018 7:00:00 PM Drug: Ceftriaxone Sodium Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Dexamethasone Sodium Phosphate Injection 12/2/2018 7:00:00 PM Drug: Dexamethasone Sodium Phosphate Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Furosemide Injection 12/2/2018 7:00:00 PM Drug: Furosemide Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Heparin Sodium Premixed Bags 12/2/2018 7:00:00 PM Drug: Heparin Sodium Premixed Bags, Revision Date: Mon, 03 Dec 2018 (Click for more...) Letermovir Injection 12/2/2018 7:00:00 PM Drug: Letermovir Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Mannitol Injection 12/2/2018 7:00:00 PM Drug: Mannitol Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Potassium Acetate Injection 12/2/2018 7:00:00 PM Drug: Potassium Acetate Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Proparacaine Hydrochloride Ophthalmic Solution 12/2/2018 7:00:00 PM Drug: Proparacaine Hydrochloride Ophthalmic Solution, Revision Date: Mon, 03 Dec 2018 (Click for more...) Reteplase Injection 12/2/2018 7:00:00 PM Drug: Reteplase Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Spironolactone Tablets 12/2/2018 7:00:00 PM Drug: Spironolactone Tablets, Revision Date: Mon, 03 Dec 2018 (Click for more...) Thrombin Topical Solution (Bovine) 12/2/2018 7:00:00 PM Drug: Thrombin Topical Solution (Bovine), Revision Date: Mon, 03 Dec 2018 (Click for more...) Vancomycin Hydrochloride Injection 12/2/2018 7:00:00 PM Drug: Vancomycin Hydrochloride Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Granisetron Hydrochloride Injection 12/2/2018 7:00:00 PM Drug: Granisetron Hydrochloride Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Pamidronate Disodium Injection 12/2/2018 7:00:00 PM Drug: Pamidronate Disodium Injection, Revision Date: Mon, 03 Dec 2018 (Click for more...) Cefuroxime Sodium Injection 11/30/2018 7:00:00 PM Drug: Cefuroxime Sodium Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Diphenhydramine Injection 11/30/2018 7:00:00 PM Drug: Diphenhydramine Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Hydromorphone Hydrochloride Injection 11/30/2018 7:00:00 PM Drug: Hydromorphone Hydrochloride Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Iron Dextran Injection 11/30/2018 7:00:00 PM Drug: Iron Dextran Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Lidocaine Injection 11/30/2018 7:00:00 PM Drug: Lidocaine Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Lidocaine with Epinephrine Injection 11/30/2018 7:00:00 PM Drug: Lidocaine with Epinephrine Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Magnesium Sulfate Injection 11/30/2018 7:00:00 PM Drug: Magnesium Sulfate Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Mepivacaine Injection 11/30/2018 7:00:00 PM Drug: Mepivacaine Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Methylene Blue 11/30/2018 7:00:00 PM Drug: Methylene Blue, Revision Date: Sat, 01 Dec 2018 (Click for more...) Morphine Injection 11/30/2018 7:00:00 PM Drug: Morphine Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Progesterone Injection 11/30/2018 7:00:00 PM Drug: Progesterone Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Promethazine Injection 11/30/2018 7:00:00 PM Drug: Promethazine Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Ropivacaine Injection 11/30/2018 7:00:00 PM Drug: Ropivacaine Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Tobramycin Sulfate Injection 11/30/2018 7:00:00 PM Drug: Tobramycin Sulfate Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Nalbuphine Injection 11/30/2018 7:00:00 PM Drug: Nalbuphine Injection, Revision Date: Sat, 01 Dec 2018 (Click for more...) Benztropine Mesylate Injection 11/29/2018 7:00:00 PM Drug: Benztropine Mesylate Injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Bupivacaine Injection 11/29/2018 7:00:00 PM Drug: Bupivacaine Injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Bupivacaine with Epinephrine Injection 11/29/2018 7:00:00 PM Drug: Bupivacaine with Epinephrine Injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Calcium Gluconate Injection 11/29/2018 7:00:00 PM Drug: Calcium Gluconate Injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Fluorescein Sodium Ophthalmic Strips 11/29/2018 7:00:00 PM Drug: Fluorescein Sodium Ophthalmic Strips, Revision Date: Fri, 30 Nov 2018 (Click for more...) Fluorouracil Injection 11/29/2018 7:00:00 PM Drug: Fluorouracil Injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Hydralazine injection 11/29/2018 7:00:00 PM Drug: Hydralazine injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Labetalol Injection 11/29/2018 7:00:00 PM Drug: Labetalol Injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Potassium Phosphate Injection 11/29/2018 7:00:00 PM Drug: Potassium Phosphate Injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Sodium Phosphate Injection 11/29/2018 7:00:00 PM Drug: Sodium Phosphate Injection, Revision Date: Fri, 30 Nov 2018 (Click for more...) Sterile Water for Injection - Small Volume Vials 11/29/2018 7:00:00 PM Drug: Sterile Water for Injection - Small Volume Vials, Revision Date: Fri, 30 Nov 2018 (Click for more...) Overtreatment of BP common upon discharge, says study 11/29/2018 8:42:06 AM Overtreatment of BP common upon discharge, says study Thu, 11/29/2018 - 08:50 ehaberkorn@aph… Thu, 11/29/2018 - 08:42 Clinicians may be over treating blood pressure (BP) in older adults admitted to the hospital for non-cardiac conditions by intensifying antihypertensive regimens at discharge, primarily in patients with previously well-controlled outpatient BP, according to results of an observational study published in BMJ. The data highlight the need for clinicians to pay close attention to discharge medications to reduce potentially harmful overtreatment of BP as older adults transition from the hospital to the home. (Click for more...) Faculty receive HSC research awards 11/29/2018 12:00:00 AM Drs Gibson and Marsh recently attended the Pharmaceutical Sciences Departmental meeting to provide several of our faculty with HSC research awards. These were for efforts demonstrated by their individual studies and group research activities. Congratulations to Drs Du, McLaughlin, Hazlehurst, and Lockman! (Click for more...) WVU Medicine and Health Sciences to host holiday celebration for faculty and staff 11/29/2018 12:00:00 AM The annual Holiday Celebration for WVU Medicine and Health Sciences employees will kick off on Thurs., Dec. 6, from 2 to 4 p.m. at The Market, located on the ground floor of the Health Sciences Center. The Market will close at 11:30 a.m. for the celebration. (Click for more...) Small Biotechs Progressing Beyond Startup Status 11/28/2018 8:40:45 PM When is a startup no longer a startup? Small biotech companies armed with a talented crop of scientists have been springing up all across the pharma landscape for the last several years, establishing buzzing hubs of innovation. Not all of them find their research efforts successful, but many do and then go on to be […] (Click for more...) Ampicillin Sodium and Sulbactam Sodium Injection 11/28/2018 7:00:00 PM Drug: Ampicillin Sodium and Sulbactam Sodium Injection, Revision Date: Thu, 29 Nov 2018 (Click for more...) Cefazolin Injection 11/28/2018 7:00:00 PM Drug: Cefazolin Injection, Revision Date: Thu, 29 Nov 2018 (Click for more...) Cefoxitin Sodium Injection 11/28/2018 7:00:00 PM Drug: Cefoxitin Sodium Injection, Revision Date: Thu, 29 Nov 2018 (Click for more...) Diclofenac 0.1% Ophthalmic Solution 11/28/2018 7:00:00 PM Drug: Diclofenac 0.1% Ophthalmic Solution, Revision Date: Thu, 29 Nov 2018 (Click for more...) Enoxaparin Sodium Injection 11/28/2018 7:00:00 PM Drug: Enoxaparin Sodium Injection, Revision Date: Thu, 29 Nov 2018 (Click for more...) Methocarbamol Tablets 11/28/2018 7:00:00 PM Drug: Methocarbamol Tablets, Revision Date: Thu, 29 Nov 2018 (Click for more...) Ondansetron Hydrochloride Injection 11/28/2018 7:00:00 PM Drug: Ondansetron Hydrochloride Injection, Revision Date: Thu, 29 Nov 2018 (Click for more...) Argatroban Injection 11/27/2018 7:00:00 PM Drug: Argatroban Injection, Revision Date: Wed, 28 Nov 2018 (Click for more...) Dorzolamide Ophthalmic Solution 11/27/2018 7:00:00 PM Drug: Dorzolamide Ophthalmic Solution, Revision Date: Wed, 28 Nov 2018 (Click for more...) Doxorubicin Injection 11/27/2018 7:00:00 PM Drug: Doxorubicin Injection, Revision Date: Wed, 28 Nov 2018 (Click for more...) Gentamicin Sulfate Ophthalmic Ointment 11/27/2018 7:00:00 PM Drug: Gentamicin Sulfate Ophthalmic Ointment, Revision Date: Wed, 28 Nov 2018 (Click for more...) Heparin Injection 11/27/2018 7:00:00 PM Drug: Heparin Injection, Revision Date: Wed, 28 Nov 2018 (Click for more...) Multiple Electrolytes Large Volume Solutions for Injection 11/27/2018 7:00:00 PM Drug: Multiple Electrolytes Large Volume Solutions for Injection, Revision Date: Wed, 28 Nov 2018 (Click for more...) Olanzapine Intramuscular Injection 11/27/2018 7:00:00 PM Drug: Olanzapine Intramuscular Injection, Revision Date: Wed, 28 Nov 2018 (Click for more...) Rosuvastatin Calcium Tablets 11/27/2018 7:00:00 PM Drug: Rosuvastatin Calcium Tablets, Revision Date: Wed, 28 Nov 2018 (Click for more...) Factors that may predict sustained efficacy after a short course of OTC PPIs 11/27/2018 3:36:58 PM Key Point:Heartburn resolution within 7 days following completion of a 2-week course of OTC proton pump inhibitor (PPI) therapy (i.e., esomeprazole) was more common in patients who had less baseline heartburn frequency, in those who had symptom resolution during the last 7 days of treatment, and in patients who had the most heartburn-free days during the 2-week treatment period, according to results of a post-hoc analysis published in BMC Gastroenterology. (Click for more...) Medications used for substance abuse disorders may reduce suicidality, crime 11/27/2018 12:09:10 PM Key Point:Use of medications for alcohol or opioid abuse (e.g., naltrexone, buprenorphine, methadone) was associated with reductions in accidental overdoses, suicidal behaviors, and crime, according to results of an observational, population-based study published in the American Journal of Psychiatry. (Click for more...) Deprescribing is the cure for ‘disease’ of polypharmacy 11/27/2018 11:17:42 AM Deprescribing is the cure for ‘disease’ of polypharmacy Tue, 11/27/2018 - 11:23 caldridgeyoung… Tue, 11/27/2018 - 11:17 Prescription drug use is rising in the United States, outpacing population growth. According to a nationwide survey published in Consumer Reports in August 2017, the number of prescriptions increased 85% over 20 years, while the population grew by 21%. Some of the increase stems from polypharmacy as 77 million baby boomers reach their 70s. (Click for more...) 0.9% Sodium Chloride 10 mL, 20 mL, and 50 mL Preservative Free Vials and Syringes 11/26/2018 7:00:00 PM Drug: 0.9% Sodium Chloride 10 mL, 20 mL, and 50 mL Preservative Free Vials and Syringes, Revision Date: Tue, 27 Nov 2018 (Click for more...) 23.4% Sodium Chloride Injection 11/26/2018 7:00:00 PM Drug: 23.4% Sodium Chloride Injection, Revision Date: Tue, 27 Nov 2018 (Click for more...) Bacteriostatic 0.9% Sodium Chloride Vials 11/26/2018 7:00:00 PM Drug: Bacteriostatic 0.9% Sodium Chloride Vials, Revision Date: Tue, 27 Nov 2018 (Click for more...) Betamethasone Acetate/Betamethasone Sodium Phosphate Suspension for Injection 11/26/2018 7:00:00 PM Drug: Betamethasone Acetate/Betamethasone Sodium Phosphate Suspension for Injection, Revision Date: Tue, 27 Nov 2018 (Click for more...) Orphenadrine Citrate Injection 11/26/2018 7:00:00 PM Drug: Orphenadrine Citrate Injection, Revision Date: Tue, 27 Nov 2018 (Click for more...) Phenytoin Sodium Injection 11/26/2018 7:00:00 PM Drug: Phenytoin Sodium Injection, Revision Date: Tue, 27 Nov 2018 (Click for more...) Rocuronium Injection 11/26/2018 7:00:00 PM Drug: Rocuronium Injection, Revision Date: Tue, 27 Nov 2018 (Click for more...) Sufentanil Injection 11/26/2018 7:00:00 PM Drug: Sufentanil Injection, Revision Date: Tue, 27 Nov 2018 (Click for more...) Selling CBD oil: Implications for pharmacy owners 11/26/2018 4:05:57 PM Selling CBD oil: Implications for pharmacy owners Mon, 11/26/2018 - 16:11 ehaberkorn@aph… Mon, 11/26/2018 - 16:05 For many pharmacy owners, having a large section of OTC products is vital to maintaining profitability. Nonprescription product management can be relatively easy with support from wholesalers and profit margins make it well worth the time and energy put into it. But cannabidiol (CBD) oil is not your average OTC product. Choosing which CBD product to sell in your pharmacy can be an intense decision and complying with the legal requirements and restrictions surrounding its sale might be headache-inducing. (Click for more...) Tackling Unmet Needs with a Proprietary Platform 11/21/2018 10:21:38 PM Since our founding back in 2006, LegoChem Biosciences (LCB) has focused on the research and development of anti-biotic, anti-coagulant, anti-fibrosis and Antibody-Drug Conjugate (ADC) therapeutics based on our proprietary platform technology, LegoChemistry™ & Conjuall™. LCB is comprised of researchers who have varied backgrounds and R&D experiences, including the development of Factive, the first US FDA-approved drug […] (Click for more...) Iopamidol Injection 11/20/2018 7:00:00 PM Drug: Iopamidol Injection, Revision Date: Wed, 21 Nov 2018 (Click for more...) Reassessing use of statins for primary prevention in older adults 11/20/2018 10:41:49 AM Key Point:In people older than age 74 years without diabetes, statin use for primary prevention was not associated with a reduction in the risk of atherosclerotic cardiovascular (CV) disease or all-cause mortality, with benefits seen only in those with diabetes who were between 75 and 84 years old, according to results of an observational study published in BMJ. (Click for more...) Pharmacists need a better understanding of generic drug approvals 11/20/2018 10:12:52 AM Key Point:An assessment of community pharmacists’ understanding of FDA therapeutic equivalence standards and bioequivalence criteria showed that many pharmacists need additional education on these topics, according to survey results published in Research in Social and Administrative Pharmacy. (Click for more...) Buspirone Tablets 11/19/2018 7:00:00 PM Drug: Buspirone Tablets, Revision Date: Tue, 20 Nov 2018 (Click for more...) Cefepime Injection 11/19/2018 7:00:00 PM Drug: Cefepime Injection, Revision Date: Tue, 20 Nov 2018 (Click for more...) Nelarabine Injection 11/19/2018 7:00:00 PM Drug: Nelarabine Injection, Revision Date: Tue, 20 Nov 2018 (Click for more...) Thiothixene Capsules 11/19/2018 7:00:00 PM Drug: Thiothixene Capsules, Revision Date: Tue, 20 Nov 2018 (Click for more...) Finding Answers Where You Least Expect Them 11/19/2018 6:58:24 PM The hard work of drug development often goes down well-worn paths that can be tedious, time-consuming and frustrating, but – with time and dedication – can yield exciting results. Sometimes, however, scientists who think outside the box find themselves taking unconventional routes in their efforts to create innovative new therapies. For some researchers, it’s about […] (Click for more...) 0.9% Sodium Chloride Large Volume Bags 11/18/2018 7:00:00 PM Drug: 0.9% Sodium Chloride Large Volume Bags, Revision Date: Mon, 19 Nov 2018 (Click for more...) 0.9% Sodium Chloride Small Volume Bags (< 150 mL) 11/18/2018 7:00:00 PM Drug: 0.9% Sodium Chloride Small Volume Bags (< 150 mL), Revision Date: Mon, 19 Nov 2018 (Click for more...) 2% Lidocaine Hydrochloride Topical Jelly 11/18/2018 7:00:00 PM Drug: 2% Lidocaine Hydrochloride Topical Jelly, Revision Date: Mon, 19 Nov 2018 (Click for more...) 5% Dextrose Injection 11/18/2018 7:00:00 PM Drug: 5% Dextrose Injection, Revision Date: Mon, 19 Nov 2018 (Click for more...) 5% Dextrose Injection (PVC-free and DEHP-free) 11/18/2018 7:00:00 PM Drug: 5% Dextrose Injection (PVC-free and DEHP-free), Revision Date: Mon, 19 Nov 2018 (Click for more...) Acetylcysteine Oral and Inhalation Solution 11/18/2018 7:00:00 PM Drug: Acetylcysteine Oral and Inhalation Solution, Revision Date: Mon, 19 Nov 2018 (Click for more...) Belladonna and Opium Suppositories 11/18/2018 7:00:00 PM Drug: Belladonna and Opium Suppositories, Revision Date: Mon, 19 Nov 2018 (Click for more...) Ciprofloxacin Oral Suspension 11/18/2018 7:00:00 PM Drug: Ciprofloxacin Oral Suspension, Revision Date: Mon, 19 Nov 2018 (Click for more...) Hepatitis B Vaccine (Recombinant) 11/18/2018 7:00:00 PM Drug: Hepatitis B Vaccine (Recombinant), Revision Date: Mon, 19 Nov 2018 (Click for more...) Lactated Ringer's Injection 11/18/2018 7:00:00 PM Drug: Lactated Ringer's Injection, Revision Date: Mon, 19 Nov 2018 (Click for more...) Methotrexate Injection 11/18/2018 7:00:00 PM Drug: Methotrexate Injection, Revision Date: Mon, 19 Nov 2018 (Click for more...) Potassium Chloride Injection 11/18/2018 7:00:00 PM Drug: Potassium Chloride Injection, Revision Date: Mon, 19 Nov 2018 (Click for more...) Sodium Fluoride Chewable Tablets 11/18/2018 7:00:00 PM Drug: Sodium Fluoride Chewable Tablets, Revision Date: Mon, 19 Nov 2018 (Click for more...) Sterile Water for Injection Large Volume Bags 11/18/2018 7:00:00 PM Drug: Sterile Water for Injection Large Volume Bags, Revision Date: Mon, 19 Nov 2018 (Click for more...) Cefpodoxime Oral Suspension 11/18/2018 7:00:00 PM Drug: Cefpodoxime Oral Suspension, Revision Date: Mon, 19 Nov 2018 (Click for more...) Protamine Injection 11/18/2018 7:00:00 PM Drug: Protamine Injection, Revision Date: Mon, 19 Nov 2018 (Click for more...) “Dear New Practitioner” 11/16/2018 12:12:35 PM “Dear New Practitioner” Mon, 11/18/2019 - 06:00 jdebruijn@APHA… Fri, 11/16/2018 - 12:12 There has been an increased effort to decrease mental health stigma and integrate mental health care into our lives like we would physical fitness. How do you as a new practitioner address mental health wit...Only allowed members have full access to this content.Log in to view full content. (Click for more...) Stop the Bleed 11/16/2018 12:00:00 AM The Jon Michael Moore Trauma Center, in partnership with the American College of Surgeons, is taking part in the national "Stop the Bleed" initiative. Participants in the programs are being trained to stop bleeding in order to prevent death from hemorrhage. (Click for more...) PCA Sterile Empty Vials and Injector 11/15/2018 7:00:00 PM Drug: PCA Sterile Empty Vials and Injector, Revision Date: Fri, 16 Nov 2018 (Click for more...) Mafenide Acetate Powder for Solution 11/15/2018 7:00:00 PM Drug: Mafenide Acetate Powder for Solution, Revision Date: Fri, 16 Nov 2018 (Click for more...) Diversity is the key to unlocking scientific innovations 11/15/2018 10:36:29 AM October 2018 started with Cern professor Alessandro Stumia’s disparaging speech about women in which he proclaimed, to a predominately female audience of physicists, that ‘physics was invented and built by men, it’s not by invitation’. In that same week, it was announced that Donna Strickland won a 2018 Nobel prize in physics for her groundbreaking […] (Click for more...) 25% Dextrose Injection 11/14/2018 7:00:00 PM Drug: 25% Dextrose Injection, Revision Date: Thu, 15 Nov 2018 (Click for more...) Desiccated Thyroid Tablets 11/14/2018 7:00:00 PM Drug: Desiccated Thyroid Tablets, Revision Date: Thu, 15 Nov 2018 (Click for more...) Diazepam Injection 11/14/2018 7:00:00 PM Drug: Diazepam Injection, Revision Date: Thu, 15 Nov 2018 (Click for more...) Dobutamine Injection 11/14/2018 7:00:00 PM Drug: Dobutamine Injection, Revision Date: Thu, 15 Nov 2018 (Click for more...) Dopamine Hydrochloride Injection 11/14/2018 7:00:00 PM Drug: Dopamine Hydrochloride Injection, Revision Date: Thu, 15 Nov 2018 (Click for more...) Epinephrine Auto-Injectors 11/14/2018 7:00:00 PM Drug: Epinephrine Auto-Injectors, Revision Date: Thu, 15 Nov 2018 (Click for more...) Fluconazole Injection 11/14/2018 7:00:00 PM Drug: Fluconazole Injection, Revision Date: Thu, 15 Nov 2018 (Click for more...) Nitrofurantoin Oral Suspension 11/14/2018 7:00:00 PM Drug: Nitrofurantoin Oral Suspension, Revision Date: Thu, 15 Nov 2018 (Click for more...) Ranitidine Injection 11/14/2018 7:00:00 PM Drug: Ranitidine Injection, Revision Date: Thu, 15 Nov 2018 (Click for more...) 90 years of penicillin – what does accidental discovery mean for R&D today? 11/14/2018 5:38:28 PM 90 years ago, an accidental discovery was made which altered medicine forever. While sorting through petri dishes in his laboratory, Alexander Fleming came across a substance we now know as penicillin, which prevented mold growing on the dish. Luck would again play a role when it came to mass production of the miracle medicine – […] (Click for more...) Leveraging Partnerships to Rescue and Develop Promising Technologies 11/13/2018 8:25:21 PM There are a number of players in the field of innovative therapeutics for cancer and inflammatory disease, but our company, 4P-Pharma, is taking a somewhat different approach than most of our competition. How our partnership model drives success Drug development has become a long, risky and expensive process. It is becoming extremely difficult to find […] (Click for more...) Alcohol Dehydrated Injection (Ethanol) 11/13/2018 7:00:00 PM Drug: Alcohol Dehydrated Injection (Ethanol), Revision Date: Wed, 14 Nov 2018 (Click for more...) Butorphanol Tartrate Injection 11/13/2018 7:00:00 PM Drug: Butorphanol Tartrate Injection, Revision Date: Wed, 14 Nov 2018 (Click for more...) Calcitriol Injection 11/13/2018 7:00:00 PM Drug: Calcitriol Injection, Revision Date: Wed, 14 Nov 2018 (Click for more...) Ciprofloxacin Injection 11/13/2018 7:00:00 PM Drug: Ciprofloxacin Injection, Revision Date: Wed, 14 Nov 2018 (Click for more...) Hepatitis A Virus Vaccine Inactivated 11/13/2018 7:00:00 PM Drug: Hepatitis A Virus Vaccine Inactivated, Revision Date: Wed, 14 Nov 2018 (Click for more...) Methylphenidate Extended-Release Oral Suspension and Chewable Tablets 11/13/2018 7:00:00 PM Drug: Methylphenidate Extended-Release Oral Suspension and Chewable Tablets, Revision Date: Wed, 14 Nov 2018 (Click for more...) Multiple Vitamins for Infusion 11/13/2018 7:00:00 PM Drug: Multiple Vitamins for Infusion, Revision Date: Wed, 14 Nov 2018 (Click for more...) Penicillin G Procaine Injection 11/13/2018 7:00:00 PM Drug: Penicillin G Procaine Injection, Revision Date: Wed, 14 Nov 2018 (Click for more...) Amino Acid Products with Electrolytes and Calcium 11/13/2018 7:00:00 PM Drug: Amino Acid Products with Electrolytes and Calcium, Revision Date: Wed, 14 Nov 2018 (Click for more...) Amino Acids in Dextrose 11/13/2018 7:00:00 PM Drug: Amino Acids in Dextrose, Revision Date: Wed, 14 Nov 2018 (Click for more...) Adolescent vaccinations not associated with fertility problems 11/13/2018 10:20:09 AM Key Point:Adolescent vaccinations with HPV, Tdap, inactivated influenza, and meningococcal conjugate (MenACWY) were not associated with an increased risk of primary ovarian insufficiency, according to results of a retrospective cohort study published in Pediatrics. (Click for more...) Folic acid and multivitamin use may decrease autism risk 11/13/2018 9:59:38 AM Key Point:Maternal exposure to folic acid and/or multivitamins (MVI) before and during pregnancy was associated with a lower risk of autism spectrum disorder in the child compared with no exposure, according to results of a case-control study published in JAMA Psychiatry. (Click for more...) Belatacept Injection 11/12/2018 7:00:00 PM Drug: Belatacept Injection, Revision Date: Tue, 13 Nov 2018 (Click for more...) Bumetanide Injection 11/11/2018 7:00:00 PM Drug: Bumetanide Injection, Revision Date: Mon, 12 Nov 2018 (Click for more...) Famotidine Injection 11/11/2018 7:00:00 PM Drug: Famotidine Injection, Revision Date: Mon, 12 Nov 2018 (Click for more...) Fluphenazine Tablets 11/11/2018 7:00:00 PM Drug: Fluphenazine Tablets, Revision Date: Mon, 12 Nov 2018 (Click for more...) Methyldopa Tablets 11/11/2018 7:00:00 PM Drug: Methyldopa Tablets, Revision Date: Mon, 12 Nov 2018 (Click for more...) Penicillamine 11/11/2018 7:00:00 PM Drug: Penicillamine, Revision Date: Mon, 12 Nov 2018 (Click for more...) Sincalide Injection 11/11/2018 7:00:00 PM Drug: Sincalide Injection, Revision Date: Mon, 12 Nov 2018 (Click for more...) Theophylline Extended-Release Tablets 11/11/2018 7:00:00 PM Drug: Theophylline Extended-Release Tablets, Revision Date: Mon, 12 Nov 2018 (Click for more...) Procainamide Hydrochloride Injection 11/10/2018 7:00:00 PM Drug: Procainamide Hydrochloride Injection, Revision Date: Sun, 11 Nov 2018 (Click for more...) Dexrazoxane Injection 11/8/2018 7:00:00 PM Drug: Dexrazoxane Injection, Revision Date: Fri, 09 Nov 2018 (Click for more...) There’s nothing more innovative than science – so why don’t we talk about it? 11/8/2018 7:38:44 AM Today is – a day where we celebrate the achievements that scientists, technologists, engineers and mathematicians have made through the centuries. It’s also a day which aims to inspire young people to go into STEM subjects by showing them how innovative each of the fields can be. In fact, that’s why November 8th was chosen: […] (Click for more...) 5% Lidocaine and 7.5% Dextrose Injection 11/7/2018 7:00:00 PM Drug: 5% Lidocaine and 7.5% Dextrose Injection, Revision Date: Thu, 08 Nov 2018 (Click for more...) Dexmedetomidine Hydrochloride 100 mcg/mL Vials for Injection 11/7/2018 7:00:00 PM Drug: Dexmedetomidine Hydrochloride 100 mcg/mL Vials for Injection, Revision Date: Thu, 08 Nov 2018 (Click for more...) Hydroxocobalamin Injection 11/7/2018 7:00:00 PM Drug: Hydroxocobalamin Injection, Revision Date: Thu, 08 Nov 2018 (Click for more...) Levetiracetam Injection 11/7/2018 7:00:00 PM Drug: Levetiracetam Injection, Revision Date: Thu, 08 Nov 2018 (Click for more...) Norepinephrine Bitartrate Injection 11/7/2018 7:00:00 PM Drug: Norepinephrine Bitartrate Injection, Revision Date: Thu, 08 Nov 2018 (Click for more...) Polyvinyl Alcohol (Artificial Tears) Ophthalmic Solution 11/7/2018 7:00:00 PM Drug: Polyvinyl Alcohol (Artificial Tears) Ophthalmic Solution, Revision Date: Thu, 08 Nov 2018 (Click for more...) AI in the life sciences – the good, the bad and the ugly 11/7/2018 3:09:52 PM Everyone in the life science industry – from the C-suite in the boardroom to scientists at the bench – are talking about the potential of AI, especially now they’re starting to see pharma companies using the technology. And we are beginning to see researchers mixing diverse kinds of data together – images, text and numeric […] (Click for more...) Pharmacy researcher leads the future of experimental therapeutics at WVU 11/7/2018 12:00:00 AM Researchers across campus are taking a One WVU approach to solving important problems and saving lives. At its core, an experimental therapeutics platform that integrates multiple disciplines from chemistry and biology to the health sciences and cancer institute. (Click for more...) Chloroprocaine Hydrochloride Injection 11/6/2018 7:00:00 PM Drug: Chloroprocaine Hydrochloride Injection, Revision Date: Wed, 07 Nov 2018 (Click for more...) Etoposide Solution for Injection 11/6/2018 7:00:00 PM Drug: Etoposide Solution for Injection, Revision Date: Wed, 07 Nov 2018 (Click for more...) Meropenem Injection 11/6/2018 7:00:00 PM Drug: Meropenem Injection, Revision Date: Wed, 07 Nov 2018 (Click for more...) 50% Dextrose Injection 11/5/2018 7:00:00 PM Drug: 50% Dextrose Injection, Revision Date: Tue, 06 Nov 2018 (Click for more...) Aminophylline Injection 11/5/2018 7:00:00 PM Drug: Aminophylline Injection, Revision Date: Tue, 06 Nov 2018 (Click for more...) Fentanyl Citrate Injection 11/5/2018 7:00:00 PM Drug: Fentanyl Citrate Injection, Revision Date: Tue, 06 Nov 2018 (Click for more...) Ketorolac Injection 11/5/2018 7:00:00 PM Drug: Ketorolac Injection, Revision Date: Tue, 06 Nov 2018 (Click for more...) Valsartan and Hydrochlorothiazide Tablets 11/5/2018 7:00:00 PM Drug: Valsartan and Hydrochlorothiazide Tablets, Revision Date: Tue, 06 Nov 2018 (Click for more...) Valsartan Tablets 11/5/2018 7:00:00 PM Drug: Valsartan Tablets, Revision Date: Tue, 06 Nov 2018 (Click for more...) Aminocaproic Acid Injection 11/5/2018 7:00:00 PM Drug: Aminocaproic Acid Injection, Revision Date: Tue, 06 Nov 2018 (Click for more...) A personalized approach to COPD management is needed 11/5/2018 4:18:30 PM Key Point:A small decline in lung function with no change in the rate of exacerbations was observed in patients with infrequent exacerbations and moderate to severe chronic obstructive pulmonary disease (COPD) who had been on long-term triple therapy and were subsequently de-escalated to dual therapy, according to data published in the American Journal of Respiratory and Critical Care Medicine. (Click for more...) A bleak picture of aspirin for primary prevention in older adults 11/5/2018 4:06:18 PM Key Point:Three publications in the New England Journal of Medicine from the ASPREE trial showed that daily use of low-dose aspirin in healthy, community-dwelling older people without documented cardiovascular (CV) disease, dementia, or physical disability did not prolong disability-free survival, did not reduce the risk of CV disease (CVD), and was associated with a higher risk of all-cause mortality and major hemorrhage compared with placebo. (Click for more...) WVU's chapter of APhA-ASP wins regional award for heart disease awareness 11/5/2018 12:00:00 AM Congratulations to the WVU School of Pharmacy's Chapter of the American Pharmacists Association – Academy of Student Pharmacists (APhA-ASP)! They earned the 2017-2018 region two award for Operation Heart activities. The award was presented this weekend at the association's Midyear Regional Meetings in Baltimore, Maryland. Operation Heart, a program to create awareness of cardiovascular disease, was launched as an official APhA-ASP National Patient Care project in 2010. Through participation in Operation Heart, student pharmacists work in their communities to encourage lifestyle modifications, monitor associated risk factors and provide education about medications for heart disease. APhA-ASP Region two includes schools of pharmacy from West Virginia, Pennsylvania, Virginia, Washington, D.C., Maryland, Delaware, and New Jersey. (Click for more...) Erythromycin Lactobionate Injection 11/4/2018 7:00:00 PM Drug: Erythromycin Lactobionate Injection, Revision Date: Mon, 05 Nov 2018 (Click for more...) Furosemide Tablets 11/4/2018 7:00:00 PM Drug: Furosemide Tablets, Revision Date: Mon, 05 Nov 2018 (Click for more...) Blue Zones Project WVU transformation presentation and Food and Friends @ 5 celebration 11/4/2018 12:00:00 AM Join Blue Zones Project Wednesday, Nov. 14, for a presentation by national speaker Nick Buettner about improving well-being across campus. The event will be held from 5:00 to 7 p.m. at the Erickson Alumni Center. Refreshments and healthy snacks provided. (Click for more...) Sodium Acetate Injection 11/3/2018 8:00:00 PM Drug: Sodium Acetate Injection, Revision Date: Sun, 04 Nov 2018 (Click for more...) Isocarboxazid Tablets 11/1/2018 8:00:00 PM Drug: Isocarboxazid Tablets, Revision Date: Fri, 02 Nov 2018 (Click for more...) Abciximab Injection 10/31/2018 8:00:00 PM Drug: Abciximab Injection, Revision Date: Thu, 01 Nov 2018 (Click for more...) Albuterol Inhalation Solution 10/31/2018 8:00:00 PM Drug: Albuterol Inhalation Solution, Revision Date: Thu, 01 Nov 2018 (Click for more...) Amiodarone Injection 10/31/2018 8:00:00 PM Drug: Amiodarone Injection, Revision Date: Thu, 01 Nov 2018 (Click for more...) Clindamycin Phosphate Injection 10/31/2018 8:00:00 PM Drug: Clindamycin Phosphate Injection, Revision Date: Thu, 01 Nov 2018 (Click for more...) Hydroxyethyl Starch in Sodium Chloride Injection 10/31/2018 8:00:00 PM Drug: Hydroxyethyl Starch in Sodium Chloride Injection, Revision Date: Thu, 01 Nov 2018 (Click for more...) Indocyanine Green 10/31/2018 8:00:00 PM Drug: Indocyanine Green, Revision Date: Thu, 01 Nov 2018 (Click for more...) Liotrix (Levothyroxine/Liothyronine T4/T3) 10/31/2018 8:00:00 PM Drug: Liotrix (Levothyroxine/Liothyronine T4/T3), Revision Date: Thu, 01 Nov 2018 (Click for more...) Mineral Oil and Petrolatum Ophthalmic Ointment 10/31/2018 8:00:00 PM Drug: Mineral Oil and Petrolatum Ophthalmic Ointment, Revision Date: Thu, 01 Nov 2018 (Click for more...) Sodium Polystyrene Sulfonate Oral or Rectal Suspension 10/31/2018 8:00:00 PM Drug: Sodium Polystyrene Sulfonate Oral or Rectal Suspension, Revision Date: Thu, 01 Nov 2018 (Click for more...) Estradiol Valerate Injection 10/31/2018 8:00:00 PM Drug: Estradiol Valerate Injection, Revision Date: Thu, 01 Nov 2018 (Click for more...) 2019 Van Liere Research Conference 10/31/2018 12:00:00 AM The 54th Annual Van Liere Research Conference (formerly the E.J. Van Liere Convocation and HSC Research Day) will be held on March 21st and 22nd, 2019 on the WVU Health Sciences Campus in Morgantown, WV. (Click for more...) Dalbavancin Injection 10/29/2018 8:00:00 PM Drug: Dalbavancin Injection, Revision Date: Tue, 30 Oct 2018 (Click for more...) Leuprolide Acetate 14-Day Kit 10/29/2018 8:00:00 PM Drug: Leuprolide Acetate 14-Day Kit, Revision Date: Tue, 30 Oct 2018 (Click for more...) Scopolamine Transdermal System 10/29/2018 8:00:00 PM Drug: Scopolamine Transdermal System, Revision Date: Tue, 30 Oct 2018 (Click for more...) Atropine Sulfate Injection 10/28/2018 8:00:00 PM Drug: Atropine Sulfate Injection, Revision Date: Mon, 29 Oct 2018 (Click for more...) Ceftazidime Injection 10/28/2018 8:00:00 PM Drug: Ceftazidime Injection, Revision Date: Mon, 29 Oct 2018 (Click for more...) Metronidazole Hydrochloride Injection 10/28/2018 8:00:00 PM Drug: Metronidazole Hydrochloride Injection, Revision Date: Mon, 29 Oct 2018 (Click for more...) Pyridoxine Hydrochloride Injection 10/28/2018 8:00:00 PM Drug: Pyridoxine Hydrochloride Injection, Revision Date: Mon, 29 Oct 2018 (Click for more...) Eflornithine Hydrochloride Cream 10/24/2018 8:00:00 PM Drug: Eflornithine Hydrochloride Cream, Revision Date: Thu, 25 Oct 2018 (Click for more...) Ethiodized Oil 10/24/2018 8:00:00 PM Drug: Ethiodized Oil, Revision Date: Thu, 25 Oct 2018 (Click for more...) Fludrocortisone Acetate Tablets 10/24/2018 8:00:00 PM Drug: Fludrocortisone Acetate Tablets, Revision Date: Thu, 25 Oct 2018 (Click for more...) Hypromellose Ophthalmic Solution 10/24/2018 8:00:00 PM Drug: Hypromellose Ophthalmic Solution, Revision Date: Thu, 25 Oct 2018 (Click for more...) Yellow Fever Vaccine 10/24/2018 8:00:00 PM Drug: Yellow Fever Vaccine, Revision Date: Thu, 25 Oct 2018 (Click for more...) WVU grad student collaborates with pharmacy professor to pursue drug to treat aggressive form of blood cancer 10/24/2018 12:00:00 AM Multiple myeloma doesn't play around. Within five years of being diagnosed with this form of blood cancer, about half of all patients die from it. And even if they initially respond well to treatment, the cancer can hide in their bone marrow for years before reemerging in a tougher-to-treat form. (Click for more...) Daptomycin Injection 10/22/2018 8:00:00 PM Drug: Daptomycin Injection, Revision Date: Tue, 23 Oct 2018 (Click for more...) Deferoxamine Injection 10/22/2018 8:00:00 PM Drug: Deferoxamine Injection, Revision Date: Tue, 23 Oct 2018 (Click for more...) Oxacillin Sodium Injection 10/22/2018 8:00:00 PM Drug: Oxacillin Sodium Injection, Revision Date: Tue, 23 Oct 2018 (Click for more...) Chlorothiazide Sodium Injection 10/22/2018 8:00:00 PM Drug: Chlorothiazide Sodium Injection, Revision Date: Tue, 23 Oct 2018 (Click for more...) Recombinant Zoster Vaccine (Shingrix) 10/18/2018 8:00:00 PM Drug: Recombinant Zoster Vaccine (Shingrix), Revision Date: Fri, 19 Oct 2018 (Click for more...) Health Sciences Campus to host Mountaineer Week events 10/17/2018 12:00:00 AM Mountaineer Week, WVU's annual celebration of West Virginia heritage and culture, will make a stop at the Health Sciences Campus on Wednesday, Oct. 24, from 11 a.m. – 1 p.m. on the Learning Center Green. (Click for more...) Piperacillin and Tazobactam Injection 10/16/2018 8:00:00 PM Drug: Piperacillin and Tazobactam Injection, Revision Date: Wed, 17 Oct 2018 (Click for more...) Haloperidol Tablets 10/14/2018 8:00:00 PM Drug: Haloperidol Tablets, Revision Date: Mon, 15 Oct 2018 (Click for more...) Meperidine Hydrochloride Injection 10/11/2018 8:00:00 PM Drug: Meperidine Hydrochloride Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Vecuronium Bromide Injection 10/11/2018 8:00:00 PM Drug: Vecuronium Bromide Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Du Publishes Two Studies That Describe an Improved Approach to Bone Marrow Transplant 10/10/2018 12:00:00 AM WVU cancer researcher and Assistant Professor of Pharmaceutical Sciences Wei Du, MD, PhD, teamed up with researchers from Cincinnati Children's Hospital Medical Center to focus on improving outcomes and reducing side effects of traditional stem cell transplant. Their work was recently published in Leukemia, one of the top journals in hematology. (Click for more...) NIH awards WVU $11.2 million for interdisciplinary cancer research 10/10/2018 12:00:00 AM West Virginia University's School of Pharmacy will soon become one of the few pharmacy schools in the nation that leads a center of biomedical research excellence. Funded by the National Institutes of Health, these centers support interdisciplinary, thematically related research into preventing, diagnosing and treating health problems. (Click for more...) Cisplatin Injection 10/9/2018 8:00:00 PM Drug: Cisplatin Injection, Revision Date: Wed, 10 Oct 2018 (Click for more...) Sterile Talc 10/8/2018 8:00:00 PM Drug: Sterile Talc, Revision Date: Tue, 09 Oct 2018 (Click for more...) Mitomycin Kit for Ophthalmic Use 10/8/2018 8:00:00 PM Drug: Mitomycin Kit for Ophthalmic Use, Revision Date: Tue, 09 Oct 2018 (Click for more...) WVU community invited to State of the University address today (10/8) 10/8/2018 12:00:00 AM WVU President Gordon Gee will deliver a State of the University address today (Oct. 8) at 3:15 p.m. at the Ruby Grand Hall, Erickson Alumni Center. Faculty, staff and students are encouraged to use the PRT, buses or carpool to the event. (Click for more...) Metoclopramide Injection 10/7/2018 8:00:00 PM Drug: Metoclopramide Injection, Revision Date: Mon, 08 Oct 2018 (Click for more...) SoP students collect empty Coca-Cola products to help WVU Medicine Children's 10/5/2018 12:00:00 AM The Industry Pharmacist Organization (IPhO) chapter at WVU started with one can and built a mountain. They've been collecting the empty Coca-Cola cans and bottles to raise money for WVU Medicine Children's. For each can or bottle donated, Coca-Cola is donating $5! The drive will continue until 3 p.m. today. Thanks to everyone at the Health Sciences Center for participating. #Let'sGo! (Click for more...) Methadone Injection 10/4/2018 8:00:00 PM Drug: Methadone Injection, Revision Date: Fri, 05 Oct 2018 (Click for more...) Pentostatin Injection 10/3/2018 8:00:00 PM Drug: Pentostatin Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Prothrombin Complex Concentrate (Kcentra) 10/3/2018 8:00:00 PM Drug: Prothrombin Complex Concentrate (Kcentra), Revision Date: Thu, 04 Oct 2018 (Click for more...) WVU APhA-ASP celebrates American Pharmacists Month 10/2/2018 12:00:00 AM October is American Pharmacists Month. WVU APhA-ASP and other student organizations will sponsor an entire month full of events to help celebrate the profession. Check out the list below and mark your calendar. (Click for more...) Pharmaceutical and Pharmacological Sciences Seminar Series 10/2/2018 12:00:00 AM Please join the West Virginia University School of Pharmacy on Oct. 9 at 1:00 p.m. in Room 3084 HSC-N for the Pharmaceutical and Pharmacological Sciences Seminar Series. John D. Imig, Ph.D., will present, "Eicosanoid Drugs: Prospects for Treating Human Diseases." Imig is a professor of pharmacology and toxicology as well as director of the Drug Discovery Center at the Medical College of Wisconsin. (Click for more...) Fomepizole Injection 10/1/2018 8:00:00 PM Drug: Fomepizole Injection, Revision Date: Tue, 02 Oct 2018 (Click for more...) 3% and 5% Sodium Chloride Large Volume Injection 9/30/2018 8:00:00 PM Drug: 3% and 5% Sodium Chloride Large Volume Injection, Revision Date: Mon, 01 Oct 2018 (Click for more...) Dipyridamole Injection 9/30/2018 8:00:00 PM Drug: Dipyridamole Injection, Revision Date: Mon, 01 Oct 2018 (Click for more...) First-year pharmacy students discuss the importance of cultural awareness in healthcare 9/27/2018 12:00:00 AM Fasting is a common practice in many religions, but what if a patient's religious beliefs keep him or her from taking a life-saving medication? How do pharmacists work around language barriers? To create cultural awareness among first-year students (P-1) and help them to navigate related challenges in a professional, caring way, the WVU School of Pharmacy has incorporated a new activity into the P-1 curriculum that addresses culture and diversity. (Click for more...) Pharmacy alumnus among homecoming awardees to be honored for extraordinary service to WVU 9/27/2018 12:00:00 AM In just 10 years, School of Pharmacy alumnus Dr. Brian Lawson (PharmD, 2008) has already provided what some would consider a lifetime of service to his alma mater. On Oct. 6, Mountaineer Nation will applaud his dedication as he accepts a prestigious award from the WVU Alumni Association during halftime of the WVU/Kansas Homecoming game. (Click for more...) Cyclosporine Capsules 9/26/2018 8:00:00 PM Drug: Cyclosporine Capsules, Revision Date: Thu, 27 Sep 2018 (Click for more...) WVU alumnus earns national award for service to the pharmacy profession 9/26/2018 12:00:00 AM The National Association of Chain Drug Stores is recognizing School of Pharmacy alumnus Mike Podgurski (BS Pharmacy, 1972) with its highest honor. Podgurski is the 2018 recipient of the Harold W. Pratt Award which recognizes individuals whose activities have contributed to the promotion, recognition and improvement of the practice of pharmacy in the chain pharmacy setting. (Click for more...) Mitoxantrone Hydrochloride Injection 9/25/2018 8:00:00 PM Drug: Mitoxantrone Hydrochloride Injection, Revision Date: Wed, 26 Sep 2018 (Click for more...) Lorazepam Oral Solution 9/25/2018 8:00:00 PM Drug: Lorazepam Oral Solution, Revision Date: Wed, 26 Sep 2018 (Click for more...) Moxifloxacin Injection 9/24/2018 8:00:00 PM Drug: Moxifloxacin Injection, Revision Date: Tue, 25 Sep 2018 (Click for more...) Free health screenings and prize opportunities at the Mountainlair 9/24/2018 12:00:00 AM Flu shots, Hemoglobin A1C tests, free health care screenings and prize opportunities will be available at the WVU Healthy Living Fair at the Mountainlair on Thursday, Sept. 27 from 10 a.m.– 2 p.m. (Click for more...) Health Sciences to host "Pandemics and Vaccinations" Expert Panel on Oct. 9 9/24/2018 12:00:00 AM Reality or fiction – just how likely is a pandemic illness? Join leading health experts as they discuss the reality of a pandemic illness on Tuesday, Oct. 9, at 4 p.m. at the Health Sciences Center's Okey Patteson Auditorium. (Click for more...) Melphalan Tablets 9/17/2018 8:00:00 PM Drug: Melphalan Tablets, Revision Date: Tue, 18 Sep 2018 (Click for more...) It's a "Code Blue" at the WVU Health Sciences Center as students train for cardiac arrest patients 9/14/2018 12:00:00 AM Witness WVU Health Sciences students and local emergency services professionals perform a "Code Blue" emergency response to a simulated cardiac arrest situation as part of National Healthcare Simulation Week. (Click for more...) Kappa Psi members receive international recognition for their academic achievments 9/12/2018 12:00:00 AM The largest professional pharmacy fraternity in the world is celebrating a group of students at the West Virginia University School of Pharmacy for their outstanding academic achievements. (Click for more...) Atenolol tablets 9/10/2018 8:00:00 PM Drug: Atenolol tablets, Revision Date: Tue, 11 Sep 2018 (Click for more...) WVU pharmacy professor to present at country's largest pain management conference 9/7/2018 12:00:00 AM Healthcare professionals attending the largest pain management conference in the United States may learn a thing or two about treating pain the "West Virginia Way." (Click for more...) WVU School of Pharmacy announces plans for Homecoming 2018 9/6/2018 12:00:00 AM The WVU School of Pharmacy will welcome alumni back to Morgantown the first weekend in October for Homecoming festivities. (Click for more...) Lidocaine Hydrochloride and 5% Dextrose Injection 9/5/2018 8:00:00 PM Drug: Lidocaine Hydrochloride and 5% Dextrose Injection, Revision Date: Thu, 06 Sep 2018 (Click for more...) Gillison to present Annual DeLynn Lecture 8/30/2018 12:00:00 AM The WVU Cancer Institute will hold its Annual DeLynn Lecture with Maura L. Gillison, MD, PhD, who will lecture on HPV and the Host Genome, at 4 pm on Tuesday, Sept. 4, in the WVU Health Sciences Center's Fukushima Auditorium (room 1901). A Q&A session will follow the lecture. The event is free and open to the public. For those who cannot attend, the event also will be webcast. (Click for more...) SoP alumni and faculty win awards at WVPA Convention 8/29/2018 12:00:00 AM Four West Virginia University School of Pharmacy alumni and two faculty members received awards at the 111th annual West Virginia Pharmacy Association (WVPA) Convention. (Click for more...) Ciprofloxacin Ophthalmic Solution 8/28/2018 8:00:00 PM Drug: Ciprofloxacin Ophthalmic Solution, Revision Date: Wed, 29 Aug 2018 (Click for more...) Vincristine Sulfate Injection 8/27/2018 8:00:00 PM Drug: Vincristine Sulfate Injection, Revision Date: Tue, 28 Aug 2018 (Click for more...) WVU Pharmacy students receive white coats 8/27/2018 12:00:00 AM Members of the West Virginia UniversitySchool of Pharmacy Class of 2022 recently received the most significant symbol of their graduate career — the white coat. (Click for more...) Atropine Ophthalmic Solution 8/26/2018 8:00:00 PM Drug: Atropine Ophthalmic Solution, Revision Date: Mon, 27 Aug 2018 (Click for more...) WVU in the news: WVU researchers working to stop cancer-growth protein 8/23/2018 12:00:00 AM Yehenew Agazie, an associate professor of biochemistry at the WVU School of Medicine, received a $1.6 million grant from the National Institutes of Health to investigate a new breast cancer treatment that is especially effective against recurrent tumors. (Click for more...) Postdoc Appreciation Event 8/23/2018 12:00:00 AM On September 18th, the Office of Research and Graduate Education will host the annual Postdoc Appreciation Celebration during the National Postdoc Appreciation week. (Click for more...) WVU Pharmacy students are winning! 8/21/2018 12:00:00 AM On August 18, four third-year students showed off their self-care knowledge at the annual West Virginia Pharmacists Association meeting in Charleston. The team comprised of Lindsay Mason, Mai Do, Lucy Luo and Shaina Kopelov won the Student Pharmacist Self Care Championship. They competed against a team from Marshall University School of Pharmacy in a jeopardy style game. The students were challenged to identify and explain aspects of the effective and safe practice of pharmacy self-care treatments. In additiion, they were asked to identify at least two over-the-counter prescription medication interactions that pharmacists should be aware of, and list three OTC medications and their use. (Click for more...) Nitroglycerin Injection 8/11/2018 8:00:00 PM Drug: Nitroglycerin Injection, Revision Date: Sun, 12 Aug 2018 (Click for more...) Multiple Vitamin Oral Liquid 8/7/2018 8:00:00 PM Drug: Multiple Vitamin Oral Liquid, Revision Date: Wed, 08 Aug 2018 (Click for more...) Selenium Injection (as Selenious Acid) 8/5/2018 8:00:00 PM Drug: Selenium Injection (as Selenious Acid), Revision Date: Mon, 06 Aug 2018 (Click for more...) Amoxicillin and Clavulanate 1000 mg/62.5 mg Extended-Release Tablets 7/31/2018 8:00:00 PM Drug: Amoxicillin and Clavulanate 1000 mg/62.5 mg Extended-Release Tablets, Revision Date: Wed, 01 Aug 2018 (Click for more...) Flurbiprofen Sodium Ophthalmic Solution 7/30/2018 8:00:00 PM Drug: Flurbiprofen Sodium Ophthalmic Solution, Revision Date: Tue, 31 Jul 2018 (Click for more...) Doctors target opioid epidemic by learning new approaches to pain treatment 7/19/2018 12:00:00 AM MORGANTOWN, W.Va. – Twice a month, healthcare providers from rural health centers all across West Virginia meet in a virtual classroom to discuss how best to help their patients cope with chronic pain. (Click for more...) Ipratropium Bromide Metered-Dose Inhaler 7/8/2018 8:00:00 PM Drug: Ipratropium Bromide Metered-Dose Inhaler, Revision Date: Mon, 09 Jul 2018 (Click for more...) Thiamine Injection 7/5/2018 8:00:00 PM Drug: Thiamine Injection, Revision Date: Fri, 06 Jul 2018 (Click for more...) Caffeine and Sodium Benzoate Injection 7/4/2018 8:00:00 PM Drug: Caffeine and Sodium Benzoate Injection, Revision Date: Thu, 05 Jul 2018 (Click for more...) Trace Elements Injection 7/4/2018 8:00:00 PM Drug: Trace Elements Injection, Revision Date: Thu, 05 Jul 2018 (Click for more...) Vitamin K (Phytonadione) Injection 7/4/2018 8:00:00 PM Drug: Vitamin K (Phytonadione) Injection, Revision Date: Thu, 05 Jul 2018 (Click for more...) Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 6/26/2018 8:00:00 PM Drug: Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, Revision Date: Wed, 27 Jun 2018 (Click for more...) Three West Virginia pharmacists named WVU School of Pharmacy's Preceptor of the Year 6/26/2018 12:00:00 AM Bill Renner, Terry Davis and Matt Pletcher received the 2018 WVU School of Pharmacy Preceptor of the Year award on Friday, June 8 at the School's annual Alumni Reunion Dinner. (Click for more...) School of Pharmacy DAP student wins national history award 6/25/2018 12:00:00 AM School of Pharmacy Direct Admit Pathway (DAP) student Brennan Lawless is off to a fast start as a West Virginia University freshman. The Daniels, West Virginia, native recently won a National History Day award. (Click for more...) Dalbavancin Injection 6/20/2018 8:00:00 PM Drug: Dalbavancin Injection, Revision Date: Thu, 21 Jun 2018 (Click for more...) Asparaginase Erwinia chrysanthemi 6/19/2018 8:00:00 PM Drug: Asparaginase Erwinia chrysanthemi, Revision Date: Wed, 20 Jun 2018 (Click for more...) Haloperidol Lactate Injection 6/19/2018 8:00:00 PM Drug: Haloperidol Lactate Injection, Revision Date: Wed, 20 Jun 2018 (Click for more...) New rural scholars program available to health professions students in West Virginia 6/14/2018 12:00:00 AM West Virginia AHEC Rural Community Health Scholars is a new, highly selective program available to 75 of West Virginia's top health professions students interested in practicing in rural or underserved communities; WVU and non-WVU students alike may participate. (Click for more...) WVU researchers identify four factors that predict chronic opioid use 5/29/2018 12:00:00 AM Four factors increase the odds that a patient will wind up on chronic opioid therapy, suggests research conducted by a team of researchers led by Nilanjana Dwibedi, assistant professor in the West Virginia University School of Pharmacy. (Click for more...) Amoxapine Tablets 5/28/2018 8:00:00 PM Drug: Amoxapine Tablets, Revision Date: Tue, 29 May 2018 (Click for more...) Oseltamivir Oral Suspension 5/28/2018 8:00:00 PM Drug: Oseltamivir Oral Suspension, Revision Date: Tue, 29 May 2018 (Click for more...) Penicillin G Benzathine / Penicillin G Procaine 5/24/2018 8:00:00 PM Drug: Penicillin G Benzathine / Penicillin G Procaine, Revision Date: Fri, 25 May 2018 (Click for more...) Pantoprazole Injection 5/22/2018 8:00:00 PM Drug: Pantoprazole Injection, Revision Date: Wed, 23 May 2018 (Click for more...) Doxycycline Hyclate Injection 5/20/2018 8:00:00 PM Drug: Doxycycline Hyclate Injection, Revision Date: Mon, 21 May 2018 (Click for more...) Thiotepa for Injection 5/13/2018 8:00:00 PM Drug: Thiotepa for Injection, Revision Date: Mon, 14 May 2018 (Click for more...) School of Pharmacy announces changes to its leadership team 5/10/2018 12:00:00 AM The West Virginia University School of Pharmacy is pleased to announce changes to its leadership team. Dr. Paul Lockman has been appointed the position of senior associate dean for research and strategic initiatives in addition to Mylan Endowed Chair of Pharmacology, while Dr. Mary Stamatakis has been appointed to senior associate dean of academic affairs and educational innovation. (Click for more...) 25% Dextrose Injection 5/9/2018 8:00:00 PM Drug: 25% Dextrose Injection, Revision Date: Thu, 10 May 2018 (Click for more...) Scopolamine Transdermal System 5/7/2018 8:00:00 PM Drug: Scopolamine Transdermal System, Revision Date: Tue, 08 May 2018 (Click for more...) MEET OUR GRADS: Erin Barthelmess 5/3/2018 12:00:00 AM Why did you choose WVU? (Click for more...) MEET OUR GRADS: Jonathan Boyles 5/3/2018 12:00:00 AM Why did you choose pharmacy as a career? (Click for more...) Hydroxyzine Hydrochloride Injection 4/29/2018 8:00:00 PM Drug: Hydroxyzine Hydrochloride Injection, Revision Date: Mon, 30 Apr 2018 (Click for more...) Procainamide Hydrochloride Injection 4/24/2018 8:00:00 PM Drug: Procainamide Hydrochloride Injection, Revision Date: Wed, 25 Apr 2018 (Click for more...) WVU Benefits Open Enrollment continues through May 15; HSC session set for April 25 4/19/2018 12:00:00 AM WVU Benefits Administration is hosting a Benefits Information Table at the Health Sciences Center in HR, G211-B on Wednesday, April 25 from 1 to 3 p.m. (Click for more...) Dr. Suresh Madhavan to receive AACP's prestigious Dawson Award for Excellence in Patient Care Research 4/16/2018 12:00:00 AM The American Association of Colleges of Pharmacy (AACP) will recognize S. Suresh Madhavan, M.B.A., Ph.D., FAPhA professor and chair of the Department of Pharmaceutical Systems and Policy at the West Virginia University School of Pharmacy, for his innovative research addressing the profound health disparities in West Virginia. He will receive the Paul R. Dawson Award for Excellence in Patient Care Research on July 23 during the Science Plenary at Pharmacy Education 2018, the AACP Annual Meeting, in Boston, Massachusetts. (Click for more...) Melphalan Tablets 4/11/2018 8:00:00 PM Drug: Melphalan Tablets, Revision Date: Thu, 12 Apr 2018 (Click for more...) Ali Rezai appointed Rockefeller Chair in Neuroscience at WVU 4/9/2018 12:00:00 AM An investiture ceremony will be held on Monday at 4 p.m. in the Pylons Lobby of the WVU Health Sciences Center. (Click for more...) Clonidine Extended-Release Tablets 3/26/2018 8:00:00 PM Drug: Clonidine Extended-Release Tablets, Revision Date: Tue, 27 Mar 2018 (Click for more...) Disopyramide Phosphate Controlled-Release Capsules 3/22/2018 8:00:00 PM Drug: Disopyramide Phosphate Controlled-Release Capsules, Revision Date: Fri, 23 Mar 2018 (Click for more...) Bendamustine Hydrochloride Injection 3/18/2018 8:00:00 PM Drug: Bendamustine Hydrochloride Injection, Revision Date: Mon, 19 Mar 2018 (Click for more...) Alumna returns to campus as guest speaker for Louis A. Luzzi Lectureship Series 3/9/2018 12:00:00 AM Dr. Joanna Stollings, a 2003 graduate of the WVU School of Pharmacy, returned to campus March 9 as guest speaker for the Lois A. Luzzi Lectureship Series. (Click for more...) Carboplatin Solution for Injection 3/7/2018 7:00:00 PM Drug: Carboplatin Solution for Injection, Revision Date: Thu, 08 Mar 2018 (Click for more...) Science advocate, author to speak at WVU 3/7/2018 12:00:00 AM Paul A. Offit, M.D., a physician-scientist who is an expert in infectious diseases, immunology, virology and vaccine and the founding director of the Autism Science Foundation, will speak on "Scientific Misadventures: Learning from the Past," at noon, Friday, March 23 in the Patteson Auditorium at WVU's Health Sciences Center. (Click for more...) Etoposide Phosphate Injection 3/5/2018 7:00:00 PM Drug: Etoposide Phosphate Injection, Revision Date: Tue, 06 Mar 2018 (Click for more...) Health in West Virginia: The Next 150 Years 3/5/2018 12:00:00 AM West Virginia University President E. Gordon Gee will join Health Sciences Vice President and Executive Dean Clay Marsh, M.D., and WVU Medicine-WVU Hospitals President and CEO Albert L. Wright Jr., at a Health Sciences Town Hall on Wed., March 28 at noon in Okey Patteson Auditorium. The event is free and open to the public. (Click for more...) Schwinghammer retiring from WVU School of Pharmacy; Slain named new chair of clinical pharmacy 3/2/2018 12:00:00 AM Dr. Douglas Slain, an infectious disease specialist and professor at the West Virginia University School of Pharmacy, will be appointed the new chairperson of the School's clinical pharmacy department. Slain succeeds Dr. Terry Schwinghammer, who will retire this spring. (Click for more...) Promethazine Injection 2/28/2018 7:00:00 PM Drug: Promethazine Injection, Revision Date: Thu, 01 Mar 2018 (Click for more...) APhA annual meeting alumni reception 2/23/2018 12:00:00 AM The WVU School of Pharmacy will host an alumni reception at the 2018 APhA annual meeting in Nashville, Tennessee. (Click for more...) CDC to offer continuing education course on vaccine immunization in Morgantown 2/21/2018 12:00:00 AM The Centers for Disease Control and Prevention is offering a continuing education course titled CDC Pink Book Training: Epidemiology and Prevention of Vaccine Preventable Diseases on April 10-11, 2018, at the Morgantown Marriott at Waterfront Place in Morgantown, West Virginia. (Click for more...) WVU researcher wins national award; examines use of multiple medications among older cancer survivors 2/20/2018 12:00:00 AM Traci LeMasters, assistant professor in the School of Pharmacy, is a recipient of the American Association of Colleges of Pharmacy's New Investigator Award, which grants funding to early-career faculty to jumpstart independent research programs. She is one of only 16 people nationwide to receive the award this year. (Click for more...) WVU School of Pharmacy professor debunks common flu-related myths 2/14/2018 12:00:00 AM The Centers for Disease Control and Prevention (CDC) "FluView" map shows the virus is currently active in all 50 states, Washington, D.C., and Puerto Rico. WVU School of Pharmacy professor Douglas Slain, specializing in infectious diseases, answers some frequently asked questions and dispels common myths. (Click for more...) WVU Festival of Ideas to host panel of six opioid crisis experts 2/12/2018 12:00:00 AM Six experts on the state's opioid crisis will take part in a panel discussion Feb. 20 in the Charleston Civic Center Little Theater as part of West Virginia University's Festival of Ideas. "Understanding the Opioid Epidemic" starts at 7:30 p.m., and is co-sponsored by The Charleston Gazette-Mail. (Click for more...) Ofloxacin Ophthalmic Solution 2/11/2018 7:00:00 PM Drug: Ofloxacin Ophthalmic Solution, Revision Date: Mon, 12 Feb 2018 (Click for more...) C1-Esterase Inhibitor (Human) Injection 1/30/2018 7:00:00 PM Drug: C1-Esterase Inhibitor (Human) Injection, Revision Date: Wed, 31 Jan 2018 (Click for more...) Indigo Carmine Injection 1/21/2018 7:00:00 PM Drug: Indigo Carmine Injection, Revision Date: Mon, 22 Jan 2018 (Click for more...) Tolmetin Capsules and Tablets 1/15/2018 7:00:00 PM Drug: Tolmetin Capsules and Tablets, Revision Date: Tue, 16 Jan 2018 (Click for more...) Folic Acid Injection 1/13/2018 7:00:00 PM Drug: Folic Acid Injection, Revision Date: Sun, 14 Jan 2018 (Click for more...) Vitamin A Injection 12/19/2017 7:00:00 PM Drug: Vitamin A Injection, Revision Date: Wed, 20 Dec 2017 (Click for more...) Penicillin G Benzathine 12/17/2017 7:00:00 PM Drug: Penicillin G Benzathine, Revision Date: Mon, 18 Dec 2017 (Click for more...) Succinylcholine Injection 12/3/2017 7:00:00 PM Drug: Succinylcholine Injection, Revision Date: Mon, 04 Dec 2017 (Click for more...) Gentamicin Injection 11/21/2017 7:00:00 PM Drug: Gentamicin Injection, Revision Date: Wed, 22 Nov 2017 (Click for more...) Hyoscyamine Sulfate Injection 11/15/2017 7:00:00 PM Drug: Hyoscyamine Sulfate Injection, Revision Date: Thu, 16 Nov 2017 (Click for more...) Sodium Nitroprusside Injection 10/10/2017 8:00:00 PM Drug: Sodium Nitroprusside Injection, Revision Date: Wed, 11 Oct 2017 (Click for more...) Etoposide Phosphate Injection 10/7/2017 8:00:00 PM Drug: Etoposide Phosphate Injection, Revision Date: Sun, 08 Oct 2017 (Click for more...) Lidocaine Topical 4% Solution 10/7/2017 8:00:00 PM Drug: Lidocaine Topical 4% Solution, Revision Date: Sun, 08 Oct 2017 (Click for more...) Topotecan capsules 10/5/2017 8:00:00 PM Drug: Topotecan capsules, Revision Date: Fri, 06 Oct 2017 (Click for more...) Fludarabine Injection 10/3/2017 8:00:00 PM Drug: Fludarabine Injection, Revision Date: Wed, 04 Oct 2017 (Click for more...) Cefpodoxime Oral Suspension 10/1/2017 8:00:00 PM Drug: Cefpodoxime Oral Suspension, Revision Date: Mon, 02 Oct 2017 (Click for more...) Papaverine Injection 10/1/2017 8:00:00 PM Drug: Papaverine Injection, Revision Date: Mon, 02 Oct 2017 (Click for more...) 70% Dextrose Injection Large Volume Bags 9/28/2017 8:00:00 PM Drug: 70% Dextrose Injection Large Volume Bags, Revision Date: Fri, 29 Sep 2017 (Click for more...) Olanzapine Intramuscular Injection 9/27/2017 8:00:00 PM Drug: Olanzapine Intramuscular Injection, Revision Date: Thu, 28 Sep 2017 (Click for more...) Rabies Vaccine 9/27/2017 8:00:00 PM Drug: Rabies Vaccine, Revision Date: Thu, 28 Sep 2017 (Click for more...) Albendazole Tablets 9/19/2017 8:00:00 PM Drug: Albendazole Tablets, Revision Date: Wed, 20 Sep 2017 (Click for more...) Ioversol Injection 9/19/2017 8:00:00 PM Drug: Ioversol Injection, Revision Date: Wed, 20 Sep 2017 (Click for more...) Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection 9/18/2017 8:00:00 PM Drug: Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, Revision Date: Tue, 19 Sep 2017 (Click for more...) Methylphenidate Hydrochloride Chewable Tablets 9/14/2017 8:00:00 PM Drug: Methylphenidate Hydrochloride Chewable Tablets, Revision Date: Fri, 15 Sep 2017 (Click for more...) Tetanus and Diphtheria Toxoids Adsorbed (Td) 9/12/2017 8:00:00 PM Drug: Tetanus and Diphtheria Toxoids Adsorbed (Td), Revision Date: Wed, 13 Sep 2017 (Click for more...) Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2% 9/5/2017 8:00:00 PM Drug: Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2%, Revision Date: Wed, 06 Sep 2017 (Click for more...) Bleomycin Sulfate Injection 8/28/2017 8:00:00 PM Drug: Bleomycin Sulfate Injection, Revision Date: Tue, 29 Aug 2017 (Click for more...) Dihydroergotamine Mesylate Injection 8/16/2017 8:00:00 PM Drug: Dihydroergotamine Mesylate Injection, Revision Date: Thu, 17 Aug 2017 (Click for more...) Oxacillin Injection 8/6/2017 8:00:00 PM Drug: Oxacillin Injection, Revision Date: Mon, 07 Aug 2017 (Click for more...) Tigecycline Injection 8/3/2017 8:00:00 PM Drug: Tigecycline Injection, Revision Date: Fri, 04 Aug 2017 (Click for more...) Dolasetron Mesylate Injection 7/13/2017 8:00:00 PM Drug: Dolasetron Mesylate Injection, Revision Date: Fri, 14 Jul 2017 (Click for more...) Levocarnitine Oral Tablets and Solution 7/9/2017 8:00:00 PM Drug: Levocarnitine Oral Tablets and Solution, Revision Date: Mon, 10 Jul 2017 (Click for more...) Methylphenidate Hydrochloride Transdermal 7/6/2017 8:00:00 PM Drug: Methylphenidate Hydrochloride Transdermal, Revision Date: Fri, 07 Jul 2017 (Click for more...) Methylprednisolone Acetate Injection 6/26/2017 8:00:00 PM Drug: Methylprednisolone Acetate Injection, Revision Date: Tue, 27 Jun 2017 (Click for more...) Tetracaine Hydrochloride Ophthalmic Drops 6/26/2017 8:00:00 PM Drug: Tetracaine Hydrochloride Ophthalmic Drops, Revision Date: Tue, 27 Jun 2017 (Click for more...) Caffeine and Sodium Benzoate Injection 6/25/2017 8:00:00 PM Drug: Caffeine and Sodium Benzoate Injection, Revision Date: Mon, 26 Jun 2017 (Click for more...) Albuterol Inhalation Solution 6/19/2017 8:00:00 PM Drug: Albuterol Inhalation Solution, Revision Date: Tue, 20 Jun 2017 (Click for more...) Haloperidol Decanoate Injection 6/14/2017 8:00:00 PM Drug: Haloperidol Decanoate Injection, Revision Date: Thu, 15 Jun 2017 (Click for more...) Estradiol Valerate Injection 6/11/2017 8:00:00 PM Drug: Estradiol Valerate Injection, Revision Date: Mon, 12 Jun 2017 (Click for more...) Oxytocin Injection 6/11/2017 8:00:00 PM Drug: Oxytocin Injection, Revision Date: Mon, 12 Jun 2017 (Click for more...) Acetazolamide Injection 6/7/2017 8:00:00 PM Drug: Acetazolamide Injection, Revision Date: Thu, 08 Jun 2017 (Click for more...) Hydralazine Injection 6/5/2017 8:00:00 PM Drug: Hydralazine Injection, Revision Date: Tue, 06 Jun 2017 (Click for more...) Ondansetron Injection 5/21/2017 8:00:00 PM Drug: Ondansetron Injection, Revision Date: Mon, 22 May 2017 (Click for more...) Cefotetan Disodium Injection 5/14/2017 8:00:00 PM Drug: Cefotetan Disodium Injection, Revision Date: Mon, 15 May 2017 (Click for more...) Atropine Sulfate Ophthalmic Solution 4/24/2017 8:00:00 PM Drug: Atropine Sulfate Ophthalmic Solution, Revision Date: Tue, 25 Apr 2017 (Click for more...) Gadoteridol Injection 4/24/2017 8:00:00 PM Drug: Gadoteridol Injection, Revision Date: Tue, 25 Apr 2017 (Click for more...) Hydroxyamphetamine Hydrobromide and Tropicamide Ophthalmic Solution 4/24/2017 8:00:00 PM Drug: Hydroxyamphetamine Hydrobromide and Tropicamide Ophthalmic Solution, Revision Date: Tue, 25 Apr 2017 (Click for more...) Intranasal Mucosal Atomization Device 4/6/2017 8:00:00 PM Drug: Intranasal Mucosal Atomization Device, Revision Date: Fri, 07 Apr 2017 (Click for more...) Amikacin Injection 4/2/2017 8:00:00 PM Drug: Amikacin Injection, Revision Date: Mon, 03 Apr 2017 (Click for more...) Ampicillin Injection 3/23/2017 8:00:00 PM Drug: Ampicillin Injection, Revision Date: Fri, 24 Mar 2017 (Click for more...) Ranitidine Injection 3/20/2017 8:00:00 PM Drug: Ranitidine Injection, Revision Date: Tue, 21 Mar 2017 (Click for more...) Meningococcal Vaccines 3/19/2017 8:00:00 PM Drug: Meningococcal Vaccines, Revision Date: Mon, 20 Mar 2017 (Click for more...) Antivenin Latrodectus Mactans (Black Widow Spider Antivenin) 3/12/2017 8:00:00 PM Drug: Antivenin Latrodectus Mactans (Black Widow Spider Antivenin), Revision Date: Mon, 13 Mar 2017 (Click for more...) Sterile Empty Vials 3/6/2017 7:00:00 PM Drug: Sterile Empty Vials, Revision Date: Tue, 07 Mar 2017 (Click for more...) Potassium Acetate Injection 2/26/2017 7:00:00 PM Drug: Potassium Acetate Injection, Revision Date: Mon, 27 Feb 2017 (Click for more...) Epinephrine Injection 2/23/2017 7:00:00 PM Drug: Epinephrine Injection, Revision Date: Fri, 24 Feb 2017 (Click for more...) Sodium Acetate Injection 2/22/2017 7:00:00 PM Drug: Sodium Acetate Injection, Revision Date: Thu, 23 Feb 2017 (Click for more...) Orphenadrine Citrate Injection 2/15/2017 7:00:00 PM Drug: Orphenadrine Citrate Injection, Revision Date: Thu, 16 Feb 2017 (Click for more...) Phenobarbital Injection 2/14/2017 7:00:00 PM Drug: Phenobarbital Injection, Revision Date: Wed, 15 Feb 2017 (Click for more...) Procainamide Hydrochloride Injection 2/13/2017 7:00:00 PM Drug: Procainamide Hydrochloride Injection, Revision Date: Tue, 14 Feb 2017 (Click for more...) Sufentanil Injection 2/12/2017 7:00:00 PM Drug: Sufentanil Injection, Revision Date: Mon, 13 Feb 2017 (Click for more...) Indocyanine Green 2/8/2017 7:00:00 PM Drug: Indocyanine Green, Revision Date: Thu, 09 Feb 2017 (Click for more...) Chloroquine Phosphate Tablets 2/5/2017 7:00:00 PM Drug: Chloroquine Phosphate Tablets, Revision Date: Mon, 06 Feb 2017 (Click for more...) Ferrous Sulfate Oral Pediatric Drops 1/30/2017 7:00:00 PM Drug: Ferrous Sulfate Oral Pediatric Drops, Revision Date: Tue, 31 Jan 2017 (Click for more...) Flumazenil Injection 1/30/2017 7:00:00 PM Drug: Flumazenil Injection, Revision Date: Tue, 31 Jan 2017 (Click for more...) Nalbuphine Injection 1/30/2017 7:00:00 PM Drug: Nalbuphine Injection, Revision Date: Tue, 31 Jan 2017 (Click for more...) 25% Dextrose Injection 1/23/2017 7:00:00 PM Drug: 25% Dextrose Injection, Revision Date: Tue, 24 Jan 2017 (Click for more...) Avibactam/Ceftazidime Injection 1/23/2017 7:00:00 PM Drug: Avibactam/Ceftazidime Injection, Revision Date: Tue, 24 Jan 2017 (Click for more...) Olanzapine Injection 1/23/2017 7:00:00 PM Drug: Olanzapine Injection, Revision Date: Tue, 24 Jan 2017 (Click for more...) 23.4% Sodium Chloride Concentrated Solution for Injection 1/12/2017 7:00:00 PM Drug: 23.4% Sodium Chloride Concentrated Solution for Injection, Revision Date: Fri, 13 Jan 2017 (Click for more...) Dibucaine Ointment 1/11/2017 7:00:00 PM Drug: Dibucaine Ointment, Revision Date: Thu, 12 Jan 2017 (Click for more...) Poliovirus Vaccine Inactivated 1/8/2017 7:00:00 PM Drug: Poliovirus Vaccine Inactivated, Revision Date: Mon, 09 Jan 2017 (Click for more...) Vitamin C Oral Syrup 1/8/2017 7:00:00 PM Drug: Vitamin C Oral Syrup, Revision Date: Mon, 09 Jan 2017 (Click for more...) Diltiazem Extended-Release Capsules (Twice-Daily Dosing) 1/5/2017 7:00:00 PM Drug: Diltiazem Extended-Release Capsules (Twice-Daily Dosing), Revision Date: Fri, 06 Jan 2017 (Click for more...) Thrombin Topical Solution (Bovine) 1/5/2017 7:00:00 PM Drug: Thrombin Topical Solution (Bovine), Revision Date: Fri, 06 Jan 2017 (Click for more...) Chlorothiazide Oral Suspension 1/4/2017 7:00:00 PM Drug: Chlorothiazide Oral Suspension, Revision Date: Thu, 05 Jan 2017 (Click for more...) Benztropine Mesylate Injection 12/21/2016 7:00:00 PM Drug: Benztropine Mesylate Injection, Revision Date: Thu, 22 Dec 2016 (Click for more...) Daptacel - Diphtheria, Tetanus Toxoid, and Acellular Pertussis Vaccine (DTaP) 12/18/2016 7:00:00 PM Drug: Daptacel - Diphtheria, Tetanus Toxoid, and Acellular Pertussis Vaccine (DTaP), Revision Date: Mon, 19 Dec 2016 (Click for more...) Haemophilus B Conjugate Vaccine 12/18/2016 7:00:00 PM Drug: Haemophilus B Conjugate Vaccine, Revision Date: Mon, 19 Dec 2016 (Click for more...) Mannitol Injection 12/18/2016 7:00:00 PM Drug: Mannitol Injection, Revision Date: Mon, 19 Dec 2016 (Click for more...) Pentacel- Diphtheria, Tetanus Toxoid, and Acellular Pertussis and Inactivated Poliovirus and Haemophilus B Conjugate Vaccine (DTaP-IPV/Hib) 12/18/2016 7:00:00 PM Drug: Pentacel- Diphtheria, Tetanus Toxoid, and Acellular Pertussis and Inactivated Poliovirus and Haemophilus B Conjugate Vaccine (DTaP-IPV/Hib), Revision Date: Mon, 19 Dec 2016 (Click for more...) Amifostine Injection 11/30/2016 7:00:00 PM Drug: Amifostine Injection, Revision Date: Thu, 01 Dec 2016 (Click for more...) BCG Live Intravesical 11/17/2016 7:00:00 PM Drug: BCG Live Intravesical, Revision Date: Fri, 18 Nov 2016 (Click for more...) Imipenem and Cilastatin Sodium 11/10/2016 7:00:00 PM Drug: Imipenem and Cilastatin Sodium, Revision Date: Fri, 11 Nov 2016 (Click for more...) Leflunomide Tablets 11/10/2016 7:00:00 PM Drug: Leflunomide Tablets, Revision Date: Fri, 11 Nov 2016 (Click for more...) Flurandrenolide Tape 11/9/2016 7:00:00 PM Drug: Flurandrenolide Tape, Revision Date: Thu, 10 Nov 2016 (Click for more...) Zolpidem Tartrate Immediate Release Tablets 11/9/2016 7:00:00 PM Drug: Zolpidem Tartrate Immediate Release Tablets, Revision Date: Thu, 10 Nov 2016 (Click for more...) 70% Dextrose Injection Large Volume Bags 11/8/2016 7:00:00 PM Drug: 70% Dextrose Injection Large Volume Bags, Revision Date: Wed, 09 Nov 2016 (Click for more...) Furosemide Injection 11/8/2016 7:00:00 PM Drug: Furosemide Injection, Revision Date: Wed, 09 Nov 2016 (Click for more...) 50% Dextrose Injection 11/6/2016 7:00:00 PM Drug: 50% Dextrose Injection, Revision Date: Mon, 07 Nov 2016 (Click for more...) Caffeine and Sodium Benzoate Injection 11/6/2016 7:00:00 PM Drug: Caffeine and Sodium Benzoate Injection, Revision Date: Mon, 07 Nov 2016 (Click for more...) Desmopressin Injection 11/6/2016 7:00:00 PM Drug: Desmopressin Injection, Revision Date: Mon, 07 Nov 2016 (Click for more...) Sodium Bicarbonate Injection 11/6/2016 7:00:00 PM Drug: Sodium Bicarbonate Injection, Revision Date: Mon, 07 Nov 2016 (Click for more...) Testosterone Cypionate Injection 11/5/2016 8:00:00 PM Drug: Testosterone Cypionate Injection, Revision Date: Sun, 06 Nov 2016 (Click for more...) Vitamin A Injection 10/30/2016 8:00:00 PM Drug: Vitamin A Injection, Revision Date: Mon, 31 Oct 2016 (Click for more...) Fluorouracil Injection 10/20/2016 8:00:00 PM Drug: Fluorouracil Injection, Revision Date: Fri, 21 Oct 2016 (Click for more...) Cytarabine Injection 10/18/2016 8:00:00 PM Drug: Cytarabine Injection, Revision Date: Wed, 19 Oct 2016 (Click for more...) Cyclopentolate and Phenylephrine Ophthalmic Solution 10/16/2016 8:00:00 PM Drug: Cyclopentolate and Phenylephrine Ophthalmic Solution, Revision Date: Mon, 17 Oct 2016 (Click for more...) Cefpodoxime 9/26/2016 8:00:00 PM Drug: Cefpodoxime, Revision Date: Tue, 27 Sep 2016 (Click for more...) Phenytoin Sodium Injection 9/26/2016 8:00:00 PM Drug: Phenytoin Sodium Injection, Revision Date: Tue, 27 Sep 2016 (Click for more...) Vinblastine Sulfate Injection 9/26/2016 8:00:00 PM Drug: Vinblastine Sulfate Injection, Revision Date: Tue, 27 Sep 2016 (Click for more...) Methylprednisolone Sodium Succinate Injection 9/25/2016 8:00:00 PM Drug: Methylprednisolone Sodium Succinate Injection, Revision Date: Mon, 26 Sep 2016 (Click for more...) Cisatracurium Besylate Injection 9/8/2016 8:00:00 PM Drug: Cisatracurium Besylate Injection, Revision Date: Fri, 09 Sep 2016 (Click for more...) Propranolol Hydrochloride Tablets 9/8/2016 8:00:00 PM Drug: Propranolol Hydrochloride Tablets, Revision Date: Fri, 09 Sep 2016 (Click for more...) Sumatriptan Nasal Spray 9/8/2016 8:00:00 PM Drug: Sumatriptan Nasal Spray, Revision Date: Fri, 09 Sep 2016 (Click for more...) Fomepizole Injection 9/7/2016 8:00:00 PM Drug: Fomepizole Injection, Revision Date: Thu, 08 Sep 2016 (Click for more...) L-cysteine Hydrochloride Injection 9/7/2016 8:00:00 PM Drug: L-cysteine Hydrochloride Injection, Revision Date: Thu, 08 Sep 2016 (Click for more...) Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 8/29/2016 8:00:00 PM Drug: Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, Revision Date: Tue, 30 Aug 2016 (Click for more...) Chlorpromazine Injection 8/22/2016 8:00:00 PM Drug: Chlorpromazine Injection, Revision Date: Tue, 23 Aug 2016 (Click for more...) 14.6% Sodium Chloride Concentrated Solution for Injection 8/17/2016 8:00:00 PM Drug: 14.6% Sodium Chloride Concentrated Solution for Injection, Revision Date: Thu, 18 Aug 2016 (Click for more...) Follitropin Beta 8/14/2016 8:00:00 PM Drug: Follitropin Beta, Revision Date: Mon, 15 Aug 2016 (Click for more...) Eptifibatide Injection 8/10/2016 8:00:00 PM Drug: Eptifibatide Injection, Revision Date: Thu, 11 Aug 2016 (Click for more...) Phenazopyridine Hydrochloride 8/5/2016 8:00:00 PM Drug: Phenazopyridine Hydrochloride, Revision Date: Sat, 06 Aug 2016 (Click for more...) Tretinoin Capsules 8/5/2016 8:00:00 PM Drug: Tretinoin Capsules, Revision Date: Sat, 06 Aug 2016 (Click for more...) Anagrelide Hydrochloride Capsules 8/3/2016 8:00:00 PM Drug: Anagrelide Hydrochloride Capsules, Revision Date: Thu, 04 Aug 2016 (Click for more...) Enalaprilat Injection 7/31/2016 8:00:00 PM Drug: Enalaprilat Injection, Revision Date: Mon, 01 Aug 2016 (Click for more...) Morphine PCA Vials 7/31/2016 8:00:00 PM Drug: Morphine PCA Vials, Revision Date: Mon, 01 Aug 2016 (Click for more...) Prochlorperazine Edisylate Injection 7/31/2016 8:00:00 PM Drug: Prochlorperazine Edisylate Injection, Revision Date: Mon, 01 Aug 2016 (Click for more...) Propranolol Injection 7/31/2016 8:00:00 PM Drug: Propranolol Injection, Revision Date: Mon, 01 Aug 2016 (Click for more...) Ofloxacin Otic Solution 7/27/2016 8:00:00 PM Drug: Ofloxacin Otic Solution, Revision Date: Thu, 28 Jul 2016 (Click for more...) 5% Dextrose Injection Large Volume Bags 7/25/2016 8:00:00 PM Drug: 5% Dextrose Injection Large Volume Bags, Revision Date: Tue, 26 Jul 2016 (Click for more...) Cardioplegic Solution for Cardiac Perfusion 7/25/2016 8:00:00 PM Drug: Cardioplegic Solution for Cardiac Perfusion, Revision Date: Tue, 26 Jul 2016 (Click for more...) Lactated Ringer's Injection 7/25/2016 8:00:00 PM Drug: Lactated Ringer's Injection, Revision Date: Tue, 26 Jul 2016 (Click for more...) Tamsulosin Hydrochloride 7/20/2016 8:00:00 PM Drug: Tamsulosin Hydrochloride, Revision Date: Thu, 21 Jul 2016 (Click for more...) Doxycycline Hyclate Injection 7/7/2016 8:00:00 PM Drug: Doxycycline Hyclate Injection, Revision Date: Fri, 08 Jul 2016 (Click for more...) Metoprolol Injection 7/7/2016 8:00:00 PM Drug: Metoprolol Injection, Revision Date: Fri, 08 Jul 2016 (Click for more...) Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment 7/7/2016 8:00:00 PM Drug: Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment, Revision Date: Fri, 08 Jul 2016 (Click for more...) Aminocaproic Acid Injection 6/29/2016 8:00:00 PM Drug: Aminocaproic Acid Injection, Revision Date: Thu, 30 Jun 2016 (Click for more...) Fenoldopam Mesylate Injection 6/22/2016 8:00:00 PM Drug: Fenoldopam Mesylate Injection, Revision Date: Thu, 23 Jun 2016 (Click for more...) Heparin Sodium Premixed Bags 6/22/2016 8:00:00 PM Drug: Heparin Sodium Premixed Bags, Revision Date: Thu, 23 Jun 2016 (Click for more...) Chloroquine Tablets 6/16/2016 8:00:00 PM Drug: Chloroquine Tablets, Revision Date: Fri, 17 Jun 2016 (Click for more...) Tropicamide 1% Ophthalmic Solution 6/15/2016 8:00:00 PM Drug: Tropicamide 1% Ophthalmic Solution, Revision Date: Thu, 16 Jun 2016 (Click for more...) Chloramphenicol Sodium Succinate Injection 6/14/2016 8:00:00 PM Drug: Chloramphenicol Sodium Succinate Injection, Revision Date: Wed, 15 Jun 2016 (Click for more...) Carvedilol Tablets 6/13/2016 8:00:00 PM Drug: Carvedilol Tablets, Revision Date: Tue, 14 Jun 2016 (Click for more...) Calcitriol Injection 6/2/2016 8:00:00 PM Drug: Calcitriol Injection, Revision Date: Fri, 03 Jun 2016 (Click for more...) 0.45% Sodium Chloride Injection Bags 5/25/2016 8:00:00 PM Drug: 0.45% Sodium Chloride Injection Bags, Revision Date: Thu, 26 May 2016 (Click for more...) 0.9% Sodium Chloride Irrigation 5/25/2016 8:00:00 PM Drug: 0.9% Sodium Chloride Irrigation, Revision Date: Thu, 26 May 2016 (Click for more...) Acamprosate Calcium Tablets 5/25/2016 8:00:00 PM Drug: Acamprosate Calcium Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Acetaminophen and Codeine Phosphate 300 mg/30 mg Tablets 5/25/2016 8:00:00 PM Drug: Acetaminophen and Codeine Phosphate 300 mg/30 mg Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Adenosine Injection 5/25/2016 8:00:00 PM Drug: Adenosine Injection, Revision Date: Thu, 26 May 2016 (Click for more...) ALCOHOL DEHYDRATED INJECTION (ETHANOL) 5/25/2016 8:00:00 PM Drug: ALCOHOL DEHYDRATED INJECTION (ETHANOL), Revision Date: Thu, 26 May 2016 (Click for more...) Amoxicillin 875 mg Tablets 5/25/2016 8:00:00 PM Drug: Amoxicillin 875 mg Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Aprepitant Capsules 5/25/2016 8:00:00 PM Drug: Aprepitant Capsules, Revision Date: Thu, 26 May 2016 (Click for more...) Atorvastatin Tablets 5/25/2016 8:00:00 PM Drug: Atorvastatin Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Atracurium Injection 5/25/2016 8:00:00 PM Drug: Atracurium Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Azathioprine Tablets 5/25/2016 8:00:00 PM Drug: Azathioprine Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Azithromycin Injection 5/25/2016 8:00:00 PM Drug: Azithromycin Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Buprenorphine Sublingual Tablets 5/25/2016 8:00:00 PM Drug: Buprenorphine Sublingual Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Bupropion Hydrochloride 24 Hour extended Release Tablets 5/25/2016 8:00:00 PM Drug: Bupropion Hydrochloride 24 Hour extended Release Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Caffeine Citrate Injection 5/25/2016 8:00:00 PM Drug: Caffeine Citrate Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Caffeine Citrate Oral Solution 5/25/2016 8:00:00 PM Drug: Caffeine Citrate Oral Solution, Revision Date: Thu, 26 May 2016 (Click for more...) Carbidopa and Levodopa Extended-Release Tablets 5/25/2016 8:00:00 PM Drug: Carbidopa and Levodopa Extended-Release Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Chorionic Gonadotropin (Human) for Injection 5/25/2016 8:00:00 PM Drug: Chorionic Gonadotropin (Human) for Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Daunorubicin Hydrochloride Injection 5/25/2016 8:00:00 PM Drug: Daunorubicin Hydrochloride Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Disopyramide Phosphate Controlled-Release Capsules 5/25/2016 8:00:00 PM Drug: Disopyramide Phosphate Controlled-Release Capsules, Revision Date: Thu, 26 May 2016 (Click for more...) Ephedrine injection 5/25/2016 8:00:00 PM Drug: Ephedrine injection, Revision Date: Thu, 26 May 2016 (Click for more...) Ethambutol Tablets 5/25/2016 8:00:00 PM Drug: Ethambutol Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Hydroxychloroquine Sulfate Tablets 5/25/2016 8:00:00 PM Drug: Hydroxychloroquine Sulfate Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Hydroxyzine Hydrochloride Injection 5/25/2016 8:00:00 PM Drug: Hydroxyzine Hydrochloride Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Labetalol Injection 5/25/2016 8:00:00 PM Drug: Labetalol Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Lidocaine Hydrochloride and 5% Dextrose Injection 5/25/2016 8:00:00 PM Drug: Lidocaine Hydrochloride and 5% Dextrose Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2% 5/25/2016 8:00:00 PM Drug: Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2%, Revision Date: Thu, 26 May 2016 (Click for more...) Lidocaine Topical 4% Solution 5/25/2016 8:00:00 PM Drug: Lidocaine Topical 4% Solution, Revision Date: Thu, 26 May 2016 (Click for more...) Memantine Hydrochloride Extended-Release Capsules 5/25/2016 8:00:00 PM Drug: Memantine Hydrochloride Extended-Release Capsules, Revision Date: Thu, 26 May 2016 (Click for more...) Mercaptopurine Tablets 5/25/2016 8:00:00 PM Drug: Mercaptopurine Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Mesna Injection 5/25/2016 8:00:00 PM Drug: Mesna Injection, Revision Date: Thu, 26 May 2016 (Click for more...) METHOTREXATE INJECTION 5/25/2016 8:00:00 PM Drug: METHOTREXATE INJECTION, Revision Date: Thu, 26 May 2016 (Click for more...) MIDAZOLAM INJECTION 5/25/2016 8:00:00 PM Drug: MIDAZOLAM INJECTION, Revision Date: Thu, 26 May 2016 (Click for more...) Mometasone Furoate Monohydrate Nasal Spray 5/25/2016 8:00:00 PM Drug: Mometasone Furoate Monohydrate Nasal Spray, Revision Date: Thu, 26 May 2016 (Click for more...) Nebivolol Tablets 5/25/2016 8:00:00 PM Drug: Nebivolol Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Nicardipine Hydrochloride Injection 5/25/2016 8:00:00 PM Drug: Nicardipine Hydrochloride Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Nimodipine Oral Solution 5/25/2016 8:00:00 PM Drug: Nimodipine Oral Solution, Revision Date: Thu, 26 May 2016 (Click for more...) Pancuronium Injection 5/25/2016 8:00:00 PM Drug: Pancuronium Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Pantoprazole Tablets 5/25/2016 8:00:00 PM Drug: Pantoprazole Tablets, Revision Date: Thu, 26 May 2016 (Click for more...) Phentolamine Mesylate for Injection 5/25/2016 8:00:00 PM Drug: Phentolamine Mesylate for Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Posaconazole Oral Suspension 5/25/2016 8:00:00 PM Drug: Posaconazole Oral Suspension, Revision Date: Thu, 26 May 2016 (Click for more...) Rocuronium Bromide Injection 5/25/2016 8:00:00 PM Drug: Rocuronium Bromide Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Secretin Injection 5/25/2016 8:00:00 PM Drug: Secretin Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Sincalide Injection 5/25/2016 8:00:00 PM Drug: Sincalide Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Sterile Water for Injection Large Volume Bags 5/25/2016 8:00:00 PM Drug: Sterile Water for Injection Large Volume Bags, Revision Date: Thu, 26 May 2016 (Click for more...) Sterile Water for Irrigation 5/25/2016 8:00:00 PM Drug: Sterile Water for Irrigation, Revision Date: Thu, 26 May 2016 (Click for more...) Succinylcholine Injection 5/25/2016 8:00:00 PM Drug: Succinylcholine Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Tacrolimus Capsules 5/25/2016 8:00:00 PM Drug: Tacrolimus Capsules, Revision Date: Thu, 26 May 2016 (Click for more...) Trace Elements Injection 5/25/2016 8:00:00 PM Drug: Trace Elements Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Valproate Sodium Injection 5/25/2016 8:00:00 PM Drug: Valproate Sodium Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Verapamil Injection 5/25/2016 8:00:00 PM Drug: Verapamil Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Zinc Injection 5/25/2016 8:00:00 PM Drug: Zinc Injection, Revision Date: Thu, 26 May 2016 (Click for more...) Acetylcholine Chloride Powder for Intraocular Solution 5/16/2016 8:00:00 PM Drug: Acetylcholine Chloride Powder for Intraocular Solution, Revision Date: Tue, 17 May 2016 (Click for more...) Albuterol Sulfate Metered Dose Inhalers 5/16/2016 8:00:00 PM Drug: Albuterol Sulfate Metered Dose Inhalers, Revision Date: Tue, 17 May 2016 (Click for more...) Amino Acid Products 5/16/2016 8:00:00 PM Drug: Amino Acid Products, Revision Date: Tue, 17 May 2016 (Click for more...) Aminocaproic Acid Oral Presentations 5/16/2016 8:00:00 PM Drug: Aminocaproic Acid Oral Presentations, Revision Date: Tue, 17 May 2016 (Click for more...) Aripiprazole Oral Disintegrating Tablets 5/16/2016 8:00:00 PM Drug: Aripiprazole Oral Disintegrating Tablets, Revision Date: Tue, 17 May 2016 (Click for more...) Benzonatate Capsules 5/16/2016 8:00:00 PM Drug: Benzonatate Capsules, Revision Date: Tue, 17 May 2016 (Click for more...) Cefazolin Injection 5/16/2016 8:00:00 PM Drug: Cefazolin Injection, Revision Date: Tue, 17 May 2016 (Click for more...) Deferoxamine mesylate injection 5/16/2016 8:00:00 PM Drug: Deferoxamine mesylate injection, Revision Date: Tue, 17 May 2016 (Click for more...) Dexamethasone 0.1% Ophthalmic Drops 5/16/2016 8:00:00 PM Drug: Dexamethasone 0.1% Ophthalmic Drops, Revision Date: Tue, 17 May 2016 (Click for more...) Dextran Low Molecular Weight (Dextran 40), 10% Injection 5/16/2016 8:00:00 PM Drug: Dextran Low Molecular Weight (Dextran 40), 10% Injection, Revision Date: Tue, 17 May 2016 (Click for more...) Digoxin Injection 5/16/2016 8:00:00 PM Drug: Digoxin Injection, Revision Date: Tue, 17 May 2016 (Click for more...) Dipyridamole Injection 5/16/2016 8:00:00 PM Drug: Dipyridamole Injection, Revision Date: Tue, 17 May 2016 (Click for more...) Iothalamate Meglumine 17.2% 5/16/2016 8:00:00 PM Drug: Iothalamate Meglumine 17.2%, Revision Date: Tue, 17 May 2016 (Click for more...) Iron Dextran Injection 5/16/2016 8:00:00 PM Drug: Iron Dextran Injection, Revision Date: Tue, 17 May 2016 (Click for more...) Meropenem Injection 5/16/2016 8:00:00 PM Drug: Meropenem Injection, Revision Date: Tue, 17 May 2016